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CHAPTER 1. INTRODUCTION 
Cardiovascular disease (CVD) remains a leading cause of death in the industrialised 
world, causing about 30% of deaths globally according to the WHO (1). Despite great 
advances in the treatment of acute coronary events and the steady decline in the 
relative proportion of fatal coronary events, the burden of CVD is growing, and the 
prevalence of cardiac risk factors such as obesity, diabetes mellitus, hypertension, 
dyslipidaemia and other lifestyle factors associated with CVD risk continues to 
increase worldwide.   
Atherosclerosis is the main pathophysiological component of CVD, and over the last 
two decades, our understanding of atherosclerosis has evolved. Today, 
atherosclerosis is indeed considered a multifactorial disorder, where inflammatory 
processes play a crucial role in the development and stability of atherosclerotic 
plaques preceding clinical symptoms of CVD.   
There are many aspects of inflammation, including the leukotrienes, that have been 
associated with atherosclerosis traits. Leukotrienes belong to a class of highly pro-
inflammatory lipid mediators that are synthesised through the 5-lipoxygenase (5-LOX) 
pathway, mainly derived from arachidonic acid (AA) and, to a more limited extent, 
eicosapentaenoic acid (EPA) – specific n-6 and n-3 polyunsaturated fatty acids 
(PUFA), respectively. Different types of PUFA give rise to different leukotrienes, and 
the 5-series leukotrienes derived from EPA are considerably less pro-inflammatory 
compared with 4-series leukotrienes derived from AA.  
Consumption of marine n-3 PUFA found in seafood has been associated with a lower 
risk of coronary heart disease (CHD) in a number of observational studies and clinical 
intervention trials, and in contrast, some studies have associated AA with a higher risk 
of CHD. Thus, it has been proposed that consumption of n-3 PUFA  may cause a shift 
in cell membrane lipids towards a higher content of EPA at the expense of AA, which 
may lead to the formation of less pro-inflammatory leukotrienes from EPA compared 
with AA.    
Further, adding to the biological complexity, genetic variations in genes coding for 
enzymes involved in the leukotriene biosynthesis have been associated with risk of 
atherosclerotic disease, and it is plausible that subjects with genetic variants may up- 
or down-regulate leukotriene formation which may in turn interact with the dietary 
intake of n-3 and n-6 PUFA. Thus, evidence suggests a complex interplay between 
genetic variants related to the leukotriene pathway and dietary intake of AA and EPA, 
and it is plausible that dietary PUFA may influence the development and risk of CHD, 
at least partly, through their formation of different leukotrienes. 
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This PhD thesis is based on four studies from the Danish cohort study Diet, Cancer 
and Health. The cohort included a total of 57,053 participants and during follow-up we 
identified 3,089 cases of incident MI. A sub-cohort of 3,500 participants was randomly 
selected to represent the cohort in study II-IV. First, we investigated the association 
of dietary fish consumption and incident MI, and next, the association between the 
content of marine n-3 PUFA in adipose tissue and incident MI. By these 
complementary methods, we evaluated both a subjective measure of fish 
consumption and an objective measure of the endogenous exposure to marine n-3 
PUFA. Secondly, we examined the association between genetic variants in the 5-LOX 
pathway and MI, a major inflammatory pathway, involved in the metabolism of AA and 
EPA. Selected single nucleotide polymorphisms (SNP) and haplotypes were explored. 
Lastly, we explored the diet-gene interaction between substrates for the 5-LOX 
pathway (EPA, AA) and a tandem repeat polymorphism in the 5-LOX pathway in 
relation to the risk of incident MI. 
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CHAPTER 2. AIMS AND HYPOTHESES 
Study I 
Aim: To examine the association of dietary fish consumption with incident MI in a 
cohort study using a semi quantitative food frequency questionnaire. 
Hypothesis: Consumption of fish, in particular intake of fatty fish, is negatively 
associated with MI. Further, the intake of marine n-3 PUFA is also negatively 
associated with MI. 
Study II 
Aim: To investigate the association between adipose tissue content of marine n-3 
PUFA and incident MI. 
Hypothesis: The content of total and individual marine n-3 PUFA (EPA, 
docosapentaenoic acid (DPA) and docosahexaenoic acid (DHA)) is negatively 
associated with MI.      
Study III 
Aim: To explore associations between 22 SNPs and one tandem repeat 
polymorphism, from four candidate genes, encoding key enzymes in the 5-LOX 
pathway and incident MI. Individual SNPs and haplotypes will be assessed.  
Hypothesis: Variant genotypes are associated with MI compared with carriers of the 
wildtype. 
Study IV 
Aim: To explore diet-gene interaction between a tandem repeat polymorphism in the 
ALOX-5 gene (rs59439148) and adipose tissue content of EPA or AA with incident 
MI. 
Hypothesis: Homozygous carriers of the variant alleles will have a higher risk of MI 
compared with carriers of wildtype alleles, and EPA will attenuate the associations, 
while AA will exacerbate the associations. 
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CHAPTER 3. BACKGROUND 
3.1. ATHEROSCLEROSIS AND CHD 
CHD refers to the diseases of the coronary arteries that supply oxygen-rich blood to 
the myocardium (1). CHD is almost exclusively caused by the development of 
atherosclerotic plaques in the coronary arteries that, over time, can cause a narrowing 
of the arterial lumen and thereby a limitation of the blood flow to the myocardium. CHD 
may also present clinically as an acute event, caused by the sudden rupture of a 
plaque, resulting in the abrupt limitation of the blood flow by an intraluminal thrombus 
and subsequently, myocardial ischemia and possibly myocardial infarction (MI) (2,3). 
For a comprehensive definition of MI, see (4).    
Atherogenesis and the formation of atherosclerotic plaques constitute a complex 
process situated in the arterial wall, as reviewed by several authors (2,3,5–9). The 
initial steps of atherogenesis involve irritative stimuli (e.g. dyslipidemia, hypertension, 
diabetes mellitus, tobacco smoking etc.) leading to the activation of vascular 
endothelium cells, facilitating the migration of leucocytes and LDL particles into the 
arterial wall (7). This cell migration and accumulation of cholesterol leads to the 
initiation of a local inflammatory response that in turn further activates endothelial cells 
and smooth muscle cells and attracts more inflammatory cells. This results in a vicious 
circle with persisting inflammation (9). As the atherosclerotic plaque develops, the 
accumulation of foam cells forms a lipid-rich core consisting of lipids, inflammatory 
cells and cellular debris from the resulting cellular apoptosis. The activation and 
proliferation of smooth muscle cells in the intima of the arterial wall, on the other hand, 
form a fibrous cap that seals the lipid-rich core from the vascular lumen (2).    
In advanced atherosclerotic plaques, cell proliferation and accumulation of lipids may 
result in clinical manifestations of the growing plaque. Usually, these manifestations 
are caused by a gradual narrowing of the vascular lumen, resulting in limited blood 
flow, and ischemia. Clinical manifestations may also involve plaque rupture and 
thrombus formation, but interestingly, it is not necessarily the flow-limiting or largest 
plaques that are associated with rupture and thrombus formation (2). Naturally, a lot 
of attention has been given to identify vulnerable plaques that seem to be 
characterised by a thin fibrous cap with little collagen tissue and few smooth muscle 
cells in the cap but, in contrast, a high number of macrophages and other inflammatory 
cells. It has been suggested by several authors that inflammation might be important 
to the stability of the fibrous cap and hence the risk of plaque rupture and acute events 
(8,9). 
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3.2. MARINE N-3 PUFA AND CHD 
Classification of marine n-3 PUFA and n-6 PUFA 
Fatty acids can be classified as saturated, monounsaturated or polyunsaturated 
according to the number of double bonds on the carbon chain (Figure 1). Furthermore, 
the configuration around the double bonds can be either cis or trans configuration, 
and while most naturally occurring fatty acids are in the cis configuration, trans fatty 
acids are produced from industrialised processing (apart from ruminant trans fatty 
acids).       
N-3 PUFA, also known as omega-3 PUFA, belong to a group of essential fatty acids 
together with n-6 PUFA which implies that these fatty acids are necessary to maintain 
normal body functions but cannot be adequately synthesised endogenously (10,11). 
They are characterised as n-3 or n-6 PUFA by the position of the first double bond 
from the methyl end at carbon atom number 3 or 6, respectively.  
N-3 PUFA can be divided into two groups of different biological origin: plants and 
seafood. Thus, alpha linolenic acid (ALA) with 18 carbons and 3 double bonds 
(C18:3n-3) is mainly derived from plants, while the major marine n-3 PUFA: EPA 
(C20:5n-3), DPA (C22:5n-3) and DHA (C22:6n-3) (Figure 1) are mainly derived from 
seafood (10,11). The marine derived n-3 PUFA are sometimes termed long chain n-3 
PUFA to differentiate them from ALA. ALA can, to a limited extend, be converted to 
EPA (12), and may have beneficial effects in relation to CHD by itself (13,14). In 
humans, EPA and DHA can be interconverted via DPA through elongation and 
desaturation or vice versa. While EPA and DHA are considered the biologically most 
important with regard to cardioprotective effects, little is known about the biological 
effects of DPA. In this report, n-3 PUFA are used as an abbreviation for marine n-3 
PUFA unless otherwise specified. 
N-6 PUFA consist mainly of linoleic acid (LA, C18:2n-6) that can be converted to AA 
(20:4n-6). The main dietary sources of LA include most vegetable oils, eggs and, for 
AA, meat and dairy products (10,15).  
The role of n-6 PUFA in CHD has been debated. Most observational studies and 
dietary intervention trials have fund a neutral or slightly beneficial effect of n-6 PUFA 
intake (16,17). However, some biomarker studies on adipose tissue content of AA, 
evaluating the endogenous exposure to AA specifically, have found a positive 
association with MI (18,19), while others did not support these findings (20,21). This 
has raised concerns about n-6 PUFA being harmful to cardiac health by potential pro-
inflammatory and pro-thrombotic effects, possibly mediated via AA and the production 
of eicosanoids (22–24).          
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Figure 1. Fatty acids, classification according to the number of double bonds. Examples 
of saturated, monounsaturated and polyunsaturated fatty acids. ALA is derived from specific 
plant oils, while EPA and DHA are mostly obtained from fish and seafood. 
Marine n-3 PUFA in CHD  
More than 40 years ago, doctors from Aalborg Hospital, H.O. Bang and J. Dyerberg, 
suggested that seafood, in particularly EPA, might reduce the risk of atherothrombosis 
(25). This was based on studies in Greenland Eskimos, showing a low prevalence of 
MI in this population along with an anti-atherogenic lipid profile and markedly reduced 
platelet reactivity compared to controls living in Denmark (25–27). Bang and Dyerberg 
attributed their findings to the diet of the Eskimos based on seafood, in particular seal 
and whale, with an extremely high content of n-3 PUFA (25,28). 
This led researchers worldwide to explore the hypothesis of a beneficial effect of n-3 
PUFA on CVD, and in particular CHD. In general, early studies supported the 
hypothesis (11,29–31) and overall, most epidemiological studies have suggested an 
inverse association between fish consumption and the risk of CHD (29–38), although 
not all studies have reported this (39,40). The evidence seems to be stronger towards 
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an inverse association of fish consumption with fatal CHD and sudden cardiac death, 
than non-fatal coronary events. A large meta-analysis by He et al. from 2004 
concluded that fish consumption was inversely associated with the incidence of fatal 
CHD in a dose-dependent manner (41).  
Epidemiological studies have been followed by a number of clinical trials with n-3 
PUFA supplements as secondary prevention of CHD. In 1989, the Diet And 
Reinfarction Trial (DART) was published (42) where 2,033 patients with MI received 
different dietary advice, including fish consumption twice a week. After a 2-year period, 
the group receiving advice of increased fish intake had a 29% reduction in overall 
mortality compared to controls. Later the Gruppo Italiano per lo Studio della 
Sopravvivenza nell'Infarto miocardico (GISSI) Prevenzione trial was undertaken, 
including 11,324 post MI patients (43). A daily supplement with 1 g n-3 PUFA (given 
as one fish oil capsule containing 0.85 g of EPA+DHA) reduced total mortality, CHD 
mortality and sudden cardiac death (43,44). Based on these and other trials, several 
scientific communities now recommend that patients with CHD should eat at least 1 g 
of n-3 PUFA daily to reduce further cardiovascular events (45,46). However, recent 
intervention trials have been less convincing towards a positive effect on CHD 
prevention, and no significant association was demonstrated between intake of n-3 
PUFA supplements and CHD (47–50). Recently, two meta-analyses was published, 
reporting a more modest effect of n-3 PUFA supplements and fish consumption than 
earlier trials have suggested (51,52). Additionally, a meta-analysis on cohort studies 
using biomarkers of n-3 PUFA, reported modest effects for EPA, DPA and DHA with 
relative risks around 0.90 for fatal CHD (53).            
A number of different mechanisms have been proposed to explain the cardioprotective 
effects of n-3 PUFA. These include effects on the vessel wall, haemostasis, plasma 
lipids and the immune system (Table 1). Some of these mechanisms may be 
complementary, and the biology of n-3 PUFA may be complex and almost certainly 
mediated through a combination of mechanisms (11,14). Trials have reported that n-
3 PUFA supplements decrease plasma triglycerides in a dose-dependent manner 
(54,55) and might reduce the fraction of atherogenic small dense LDL particles (56). 
Indeed, a dose-dependent reduction on triglycerides is perhaps the best documented 
effect of marine n-3 PUFA, and in light of the current focus on remnant lipoproteins in 
atherogenesis, this might be of importance. Studies also suggest an antithrombotic 
effect of n-3 PUFA supplements, by reducing platelet reactivity and switching the 
production of thromboxanes and prostaglandins towards a more anti-aggregatory 
profile (11,57–59). It has also been suggested that n-3 PUFA prevent arrhythmias 
(44,60) and increase heart rate variability (61), which might be an important 
mechanism in explaining an effect of n-3 PUFA on sudden cardiac death. Finally, it 
has been demonstrated that n-3 PUFA are incorporated into atherosclerotic plaques, 
and a study by Thies et al. showed that a supplement of 1.4 g/day n-3 PUFA, prior to 
carotid endarterectomy, resulted in thickening of the fibrous cap and less macrophage 
infiltration in carotid plaques (62) suggesting increased plaque stability. 
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Atherosclerosis has indeed been recognised as a multifactorial disease involving 
inflammatory processes (5,6), and thus the immunomodulatory properties of n-3 
PUFA might be important in this respect.  
Table 1. Proposed mechanisms for the cardioprotective effects of n-3 PUFA. 
- Anti-atherosclerotic 
- Anti-inflammatory 
- Anti-aggregatory 
- Lowering of platelet reactivity 
- Lowering of triglycerides 
- Anti-arrhythmic 
- Lowering of blood pressure 
 
Despite a fair amount of clinical trial evidence together with animal and in vitro 
experiments, the role of n-3 PUFA in the prevention of CHD is still debated. Notably, 
important discrepancies exist between secondary prevention trials and 
epidemiological studies from a primary prevention point of view and furthermore there 
is a gap between the findings from early trials compared with more recent trials. For 
reviews on n-3 PUFA and its role in CVD see (11,14,52,63–68). 
3.3. THE 5-LIPOXYGENASE PATHWAY AND CHD 
Biosynthesis of leukotrienes 
Leukotrienes are known as highly pro-inflammatory lipid mediators and belong to a 
group of biochemically active substances called eicosanoids, also including 
thromboxanes, prostaglandins and lipoxins, among others. As the name implies, the 
leukotrienes are mainly produced by leukocytes, in particular monocytes, 
granulocytes, mast cells and dendritic cells (69,70). When leukocytes are activated, 
AA is liberated from cell membrane phospholipids by phospholipase A2. 
Subsequently, leukotrienes are produced via LOX enzymes where 5-LOX, one of six 
different LOX pathways found in humans, has been associated with inflammatory 
disease and CHD (69). The 5-LOX pathway consists of four key enzymes, where 
arachidonate 5-lipoxygenase (ALOX-5) and the 5-lipoxygenase activating protein 
(FLAP) constitute the first enzymatic step that metabolise AA and EPA. ALOX-5 
constitutes the enzymatic activity but is dependent on activation by FLAP. This first 
enzymatic step is also the rate limiting step in the pathway. By a two-step process AA 
is oxidised by the enzymatic complex into an intermediary product, leukotriene A4 
(LTA4). LTA4 is highly unstable and therefore rapidly converted by either leukotriene 
C4 synthase (LTC4-S) or leukotriene B4 hydrolase (LTB4-H) resulting in the formation 
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of either cysteinyl leukotrienes (CysLT) or leukotriene B4 (LTB4), respectively (Figure 
2) (69). While AA is the most abundant in membrane phospholipids, EPA serves as 
an alternative substrate for LOX enzymes, and because of this biochemical 
resemblance with AA, EPA functions as a competitive inhibitor of AA metabolism (71). 
Interestingly, leukotrienes derived from EPA are substantially less potent, and thus 
leukotrienes derived from EPA are generally far less pro-inflammatory compared to 
corresponding leukotrienes from AA (72,73). E.g. leukotriene B5 (LTB5) derived from 
EPA was shown to be more than 30 times less active as chemoattractant compared 
to LTB4 derived from AA (73). 
Figure 2. Schematic outline of the 5-lipoxygenase pathway. Arachidonic acid (AA), or 
alternatively eicosapentaenoic acid (EPA), is metabolised by 5-lipoxygenase (5-LOX) enzymes 
forming different leukotrienes. In the first enzymatic step, AA or EPA is oxidised by an 
enzymatic complex consisting of arachidonate 5-lipoxygenase and an activating protein 
(FLAP), forming an unstable intermediate (leukotriene A). Next, leukotriene A is rapidly 
converted to either leukotriene B or the cysteinyl leukotrienes by either leukotiene A4-hydrolase 
or leukotriene C4-synthase, respectively. Importantly, the 5-series leukotrienes derived from 
EPA are far less pro-inflammatory compared to the 4-series leukotrienes derived from AA.     
Linking the 5-LOX pathway and atherosclerosis     
Evidence suggesting a link between the 5-LOX pathway along with the bioactive 
leukotrienes and the development of atherosclerosis and atherothrombotic disease 
has been presented at multiple levels. For recent reviews see (69,74–77). Evidence 
includes animal, in-vitro and human studies. Thus, in a mouse model prone to 
atherosclerosis, it was demonstrated that the knock-out of the ALOX-5 gene led to a 
high resistance against development of atherosclerosis (78). Furthermore, in a similar 
mouse model, another study reported a decrease in atherosclerosis from inhibition of 
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FLAP (79). Other aspects of the 5-LOX pathway have been implicated in 
atherosclerosis traits in animal studies, including the leukotriene B4 receptor (80,81). 
Human studies have confirmed the presence of 5-LOX enzymes in atherosclerotic 
plaques, and interestingly, Spanbroek et al. showed that levels of ALOX-5 were higher 
in more advanced plaques (82). Furthermore, high levels of ALOX-5 and LTA4-H in 
human plaques have been associated with symptoms of plaque instability (83,84), 
suggesting a key role of the 5-LOX pathway in late stages of atherosclerosis and acute 
atherothrombotic events. 
Leukotrienes produced from the 5-LOX pathway promotes inflammation which may 
be important in atherothrombotic disease as it may enhance plaque progression and 
affect the stability of plaques. LTB4 is among the strongest known chemotactic agents, 
and as such, it may mediate monocyte infiltration into the atherosclerotic plaque 
(80,85). Actions of LTB4 are mediated through the BLT1 and BLT2 receptors that have 
been found on most types of leukocytes found in atherosclerotic lesions (69,85,86). 
BLT receptors are normally present at low levels in the resting endothelial cell, but 
activated vascular endothelium has been reported to upregulate BLT-receptor 
expression, and LTB4 itself has been shown to induce this upregulation which may 
suggest an involvement of LTB4 in early stages of atherogenesis (69,86). Additionally, 
smooth muscle cells and endothelial cells in atherosclerotic plaques also express BLT 
receptors. Thus, it is plausible that LTB may exert their biological effects via the BLT 
receptors in the setting of atherosclerosis. CysLT elicit their biological actions via two 
CysLT receptors (CysLT-1 and -2) which are present on most leukocytes, in particular 
mast cells, but are also found on smooth muscle cells (85,86). CysLTs are well known 
mediators of inflammation in asthma, however, CysLT has also been implicated in 
atherosclerosis where they have been suggested to increase vascular permeability 
and enhance inflammation (70,85). Furthermore, CysLT have been associated with 
vasoconstriction in atherosclerotic coronary arteries but not in normal coronary 
arteries without atherosclerosis (87).    
In summary, the 5-LOX pathway is present in vascular lesions and probably 
upregulated concurrently with plaque advancement. Leukotrienes elicit a number of 
pro-inflammatory effects, and evidence suggests that leukotrienes are involved in 
leukocyte migration, activation and proliferation in atherogenesis. Inflammatory stimuli 
in general have been suggested to play an important role in plaque development and 
in destabilisation of plaques. Figure 3 summarises the suggested involvement of the 
5-LOX pathway and leukotrienes in atherogenesis.  
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Figure 3. Suggested roles of leukotrienes in the development of atherosclerosis. 
Monocytes enter the vascular endothelium, and a cascade of inflammatory stimuli activates 
monocytes that develop into foam cells. The 5-LOX pathway in activated leukocytes produces 
leukotrienes among other pro-inflammatory substances that promote inflammation and further 
enhance leukotriene production, creating a vicious circle. Reproduced with permission from 
(De Caterina et al. N Engl J Med 2004; 350:4-7), Copyright Massachusetts Medical Society. 
3.4. GENETIC POLYMORPHISMS IN THE 5-LOX PATHWAY 
Initial animal and human biochemical studies fuelled the search for genetic 
associations between 5-LOX polymorphisms and CVD endpoints. A number of 
epidemiological studies have been undertaken examining the four candidate genes, 
encoding the key enzymes directly involved in the 5-LOX pathway. 
ALOX-5. Most attention has been focused on ALOX-5 and FLAP, the rate-limiting step 
in the pathway. Thus, Dwyer et al. (88) examined a tandem repeat polymorphism in 
the promoter region of ALOX-5, containing a varying number of SP1 transcription 
factor binding motifs (5’-GGGCGG-3’) and found variant alleles to be associated with 
higher intima-media thickness of the carotid arteries, a marker of atherosclerosis, 
compared to carriers of two wild type alleles. This polymorphism has been 
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investigated in a number of other studies with different endpoints, including ischemic 
stroke and MI (89–93). Results have been inconsistent, but interestingly, significant 
diet-gene interaction between 5-LOX substrates and the tandem repeat has been 
reported by two studies (88,89). Other polymorphisms in ALOX-5 have also been 
examined. Thus, two studies examined a number of SNPs designed to cover the 
genetic variation across ALOX-5 (92,94), but no consistent associations with CVD 
endpoints, except for SNPs closely linked to the tandem repeat, were reported.  
FLAP. The deCODE investigators were the first to highlight 5-LOX genes in a genome-
wide association study (95–97). Thus, FLAP was identified as an important gene 
involved in atherothrombotic disease. The group reported two haplotypes (Hap-A and 
Hap-B) that were associated with higher risk of MI and stroke among carriers in two 
independent cohorts (Icelandic (Hap-A) and British (Hap-B)) (95). Later, these results 
were replicated in a Scottish population with support for Hap-A but not for Hap-B (96). 
Following the first studies by the deCODE investigators, other studies have 
investigated FLAP, genotyping the SNPs selected by the deCODE investigators. 
Some studies supported the associations (98–102), while others did not find these 
haplotypes to be associated with the risk of MI or stroke (92,94,103,104). Most studies 
found associations for haplotypes rather than individual SNPs, and though few studies 
also reported associations for SNPs, no consensus has been obtained pointing 
towards a functional polymorphism.     
LTA4-H. The deCODE investigators also investigated the LTA4-H gene and identified 
a risk haplotype (Hap-K) for MI (97). This haplotype was tested by other investigators 
(92,104) supporting the findings from the Islandic cohort. In a study by Zhao et al. 
(105), the same SNPs as selected by the deCODE group were studied, but no 
association between carrier status of Hap-K and carotid intima-media thickness was 
found. However, the group defined a new haplotype (Hap-E) that was associated with 
a lower risk of atherosclerosis among carriers compared with non-carriers. The same 
group tested interaction between intake of n-3 and n-6 PUFA with Hap-E in a 
population of American Indians, and reported a significant diet-gene interaction for this 
haplotype (106).  
LTC4-S. In LTC4-S, two specific SNPs (rs730012 and rs3776944), located close to 
the promotor region of the gene, have been investigated. A Danish cohort study by 
Freiberg et al. found rs730012 variants negatively associated with ischemic stroke, 
while rs3776944 was positively associated with the risk of stroke (107). However, this 
could not be confirmed in two other studies where rs730012 was positively associated 
with markers of atherosclerosis and ischemic stroke (108,109). 
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4.1. STUDY POPULATION 
The Diet, Cancer and Health study 
The Diet, Cancer and Health study is a prospective cohort study with the primary 
objective of analysing the etiological role of diet in the development of cancer (110). 
Eligible participants were born in Denmark, living in the urban areas of Copenhagen 
and Aarhus and not registered with a cancer diagnosis in the Danish Cancer Registry 
at the time of invitation. In total, 160,725 persons aged 50-64 years were invited 
between December 1993 and May 1997. A letter of invitation describing the study was 
sent to each potential participant, and if invitees did not respond after three weeks, 
one reminder was sent after which no further attempt was made to recruit the subject. 
A unique ten digit personal registration number for each subject was retrieved from 
the Civil Registration System to establish future linkage between eligible subjects and 
National Registries. A total of 57,053 (35%) accepted the invitation and were enrolled 
into the study. Participants were followed until the end of July 2013.  
For the studies included in this thesis, we excluded participants if a cancer diagnosis 
was reported, that was not already recorded in the cancer registry at the time of 
invitation, in line with the intention-to-include criteria. We also excluded participants 
registered with a predefined endpoint (previous MI or cardiac arrest).  
From the cohort, a randomly selected sample of 3,500 participants was drawn. This 
made up the "sub-cohort" that was used to represent the cohort in nested case-cohort 
designs. This strategy was used when including adipose tissue biopsies and 
information on genotype in the analyses (study II-IV). In study I analyses were based 
on the entire cohort. Figure 3 illustrates the selection process for all four studies 
included in this thesis. 
The study was conducted in accordance with the Helsinki Declaration and approved 
by the regional ethics committees. 
Baseline questionnaires 
At baseline, each participant filled in two detailed questionnaires, a background and a 
dietary questionnaire. To ensure that unclear or missing responses were minimised, 
both questionnaires were checked with an interviewer.  
The background questionnaire included detailed information on socio-economic 
status, e.g. type and length of education, line of occupation. A variety of lifestyle 
factors were recorded, such as smoking status / tobacco use, alcohol consumption, 
physical activity, educational level and occupation. Furthermore, health information 
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was collected including family history of CVD, disease diagnosed by a physician and 
use of medication with focus on lipid lowering, anti-hypertensive and anti-diabetic 
drugs.     
The dietary questionnaire comprised of a detailed 192-point semi-quantitative food 
frequency questionnaire, including 26 specific questions regarding intake of fish and 
food products containing fish, at baseline. The questionnaire has been validated and 
described in detail elsewhere (111). Participants were asked to estimate their daily 
intake of foods in natural units such as pieces of fruit, slices of bread and glasses of 
different drinks. For mixed dishes and meals, sex-specific portion sizes were 
calculated using data from a calibration study. By multiplying the frequencies of intake 
by the portion size, an individual average intake in g/day of all foods and nutrients was 
calculated. Different species of fish were categorised as either lean or fatty according 
to their content of marine n-3 PUFA, below or above 1 g/100 g. In the Diet, Cancer 
and Health study cohort, fatty fish intake was mainly comprised of herring, 
salmon/trout and mackerel, while lean fish was comprised mainly of plaice/flounder 
and cod (36). The intake of herring in the Danish population is particularly high 
compared to most other countries, whereas the intake of other species, e.g. sardines, 
were relatively low. The dietary intake of specific nutrients, including total and 
individual marine n-3 PUFA (EPA, DPA and DHA) was calculated using the software 
FoodCalc (112) based on Danish food composition tables. 
Outcome assessment 
We identified all participants in the cohort who were registered with an incident 
diagnosis of MI in the Danish National Patient Registry (NPR) and/or the Danish 
Causes of Death Registry (CDR), according to the International Classification of 
Disease (ICD) 8 (410.00-410.99) or ICD-10 (I21.0-I21.9) coding, during the study 
period (Figure 4). Furthermore, all cases of cardiac arrest (ICD-8: 427.27 or ICD-10: 
I46.0-I46.9) were included if the arrest was considered to be of cardiac origin after 
validation. The NPR and the CDR hold information on diagnoses and procedures, and 
causes of death, respectively. Both registries classify diseases according to the ICD. 
The ICD 8th edition was used until January 1995, when the ICD 10th edition was 
implemented. In the NPR, discharge diagnoses from in-hospital patients have been 
registered since 1977, and since 1995 diagnoses from emergency rooms and out-
patient visits have been recorded as well. At present, the NPR has been updated until 
the 31st July 2013, and the CDR has been updated until the 31st of December 2011. 
A previous study validated the diagnoses of first-time MI until 31st of December 2003 
(113). From this study, an algorithm was established to evaluate new cases from 
January 2004 to July 2013. 
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Figure 4. Case identification. Flow chart illustrating the identification and validation of cases. 
By personal identification numbers we identified all participants with a diagnosis of incident 
myocardial infarction (MI) or cardiac arrest from two national registries (NPR & CDR), and 
secondly, all cases were validated by review of medical journals or by an algorithm.  
The algorithm takes advantage of the previously mentioned validation study that found 
a high positive predictive value for the diagnosis of MI when recorded as in-hospital 
cases (PPV=92,4%), and therefore all new cases with the diagnoses of I21.x (MI), 
given from a ward, registered in the NPR were readily accepted as new cases of MI. 
Potential cases with an I21.x diagnosis from out-patient clinics and emergency rooms 
or the CDR and the I46.x (cardiac arrest) which potentially could represent a fatal MI 
were validated. The validation was performed using an Excel spreadsheet containing 
all diagnoses and interventional procedures recorded in the NPR for each potential 
case. Each subject was evaluated individually, and it was decided whether the subject 
could be considered a potential case or not. Our point of view was that every subject 
with an I21 or I46 diagnosis was a potential case of MI unless data suggested 
otherwise. For non-fatal events, the registered events/procedures could, in most 
cases, clarify the diagnosis, but for fatal events we could only rely on information prior 
to the event. For each potential case it was decided whether the diagnosis was highly 
likely or "just" possible. Possible cases included potential cases that could not be ruled 
out as cases but neither could be regarded as a highly likely case. Thus, some 
misclassification was inevitable, but most likely, misclassification of non-cases as 
possible cases would tend to blunt the association between the intake/adipose tissue 
content of n-3 PUFA and incident MI. Both probable and possible cases were included 
as cases (n=332). In summary, 1,670 subjects were accepted as cases without 
validation because the diagnoses of MI were given by a ward, while 636 potential 
cases were validated, of which 332 were classified as cases whereas 304 were 
classified as non-cases (Table 2). 
Table 2. Case validation after December 2003 based on the validation study by Joensen 
et al. (113). 
 Validation No validation Total 
Non-case 304 - 304 
Case 332 1,670 2,002 
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4.2. ADIPOSE TISSUE ANALYSES (STUDY II-IV) 
An adipose tissue biopsy was taken from the buttocks of all participants using a luer 
lock system (Terumo, Terumo Corp, Tokyo, JP) consisting of a needle, a venoject 
multisample luer adaptor, and an evacuated blood tube, according to the method of 
Beynen and Katan (114). Samples were flushed with nitrogen and stored at -150°C 
until analysis. When analysed, biopsies were thawed and preheated at 50°C for 10 
min. Subsequently, the fat was dissolved in heptane at 50°C, and fatty acids were 
transesterified by 2 mol/L KOH (potassium hydroxide) in methanol at 50°C for 2 min, 
according to IUPAC standard methods for analysis of oils, fats, and derivatives. Fatty 
acid composition was determined by gas chromatography using a Varian 3900 GC 
with a CP-8400 autosampler (Varian, Middleburg, NL) equipped with a flame 
ionization detector. Split injection mode, a CP-sil 88, 50 m x 0.25 mm ID capillary 
column, temperature programming from 90°C to 210°C, and constant flow were used. 
Helium was used as carrier gas. Commercially available standards (Nu-chek-Prep, 
Inc., Minnesota, US) were used to identify the individual fatty acids. The method has 
been described in detail previously (35).  
The content of fatty acids were expressed as weight percent of total fatty acids, and 
the inter assay coefficients of variation were 6.4%, 3.5%, 4.1% and 3.2% for EPA, 
DPA, DHA and AA, respectively. Analyses of adipose tissue biopsies were performed 
for all cases of MI and a randomly selected sub-cohort (n=3,500). 
4.3. GENOTYPING (STUDY III-IV) 
Selection of SNPs and DNA extraction 
From a review of the current literature, we selected four candidate genes to examine 
the 5-LOX pathway (ALOX-5, FLAP, LTA4-H and LTC4-S). Next, 22 SNP markers 
were selected based on previously reported associations with CVD, with preference 
for CHD, and a confirmed minor allele frequency (MAF) > 0.05 in Caucasians. 
From whole blood, DNA was extracted using KleargeneTM XL DNA extraction kit (LGC 
Genomics, Queens Road, Teddington, Middlesex, UK). The Kleargene method is 
based on detergent-driven cell lysis, followed by guanidinium isothiocyanate-mediated 
DNA binding to silica. Next, contaminants were removed by washing and DNA was 
subsequently eluted into a low salt buffer. Extracted DNA was stored at -20C. DNA 
extraction was performed for all cases of MI and a randomly selected sub-cohort 
(n=3,000).  
MARINE N-3 FATTY ACIDS AND GENETIC VARIANTS IN THE 5-LIPOXYGENASE PATHWAY 
28
 
Sequencing 
The tandem repeat polymorphism was analysed by microtitre plate (MTP)-sequencing 
technique, using standard 96-well plates. PCR-products were prepared from genomic 
DNA, using MyTaqTM DNA polymerase (Bioline US Inc.) along with the following 
primers:   
 5’-TCAGGAGAGAACGAGTGAAC-3’ (forward)  
 5’-GTCCAGGTGTCCGCATC-3’ (reverse).  
Forty reaction cycles were performed at 55C. From the PCR-products, sequencing 
was done using an ABI 3730XL DNA analyser (Thermo Fischer Scientific Inc.), and 
Chromatograms were interpreted by a trained laboratory technician, identifying the 
number of tandem-repeats for each allele. In case of uncertainty, the chromatograms 
were rechecked by another technician, and results were discussed and agreed upon. 
KASP genotyping analyses 
SNP genotyping was performed by LGC Genomics using the commercially available 
KASPTM genotyping assay. KASP is based on a competitive, allele specific PCR 
genotyping technique with a homogenous fluorescent-based reporting system (115). 
The KASP Primer mix, containing the allele specific forward primers and a universal 
reverse primer, was mixed with the KASP Master mix, containing the taq polymerase 
enzyme and the passive reference dyes, FAMTM and HEXTM. The reaction mix was 
aliquoted to standard 96-well plates containing DNA samples from the study cohort, 
and at least one "no template control" per plate. PCR was performed, and the 
fluorescent signal was analysed using a BMG PHERAstar plate reader (BMG Labtech 
Ltd., Aylesbury, UK). The analysis was performed according to the protocol provided 
by LGC Genomics (116). SNP alleles correspond to the positive/forward DNA strand 
according to dbSNP, human assembly GRCh38.p2 (117). 
4.4. STATISTICS 
The endpoint in all the studies was time to incident (first-time) MI. Time-to-event data 
were analysed in a cohort design (Study I) using Cox proportional hazards multivariate 
regression models with age as the time axis and delayed entry. Age was regarded as 
the most important time related risk factor for MI and therefore used as time axis to 
properly adjust for this co-variate in the models. Participants were treated as "at risk" 
from baseline until endpoint, death, emigration or end of follow-up occurred.  
For Study II-IV we used a nested case-cohort design. To account for the smaller 
subsample of the cohort, we used a weighting scheme, assigning weights to each 
non-case member of the sub-cohort, and robust variance estimates were calculated 
as described by Kalbfleisch and Lawless (118). 
Analyses were conducted for the entire cohort and stratified by sex whenever 
considered methodologically appropriate. The proportional hazards assumption was 
checked by visual inspection of log-log plots and by graphical evaluation of scaled 
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Schoenfeld residuals, with no significant violations. P-values (two-tailed) <0.05 were 
considered statistically significant. The latest version of STATA (StataCorp, College 
Station, TX, US) was used as statistical software. 
Model selection 
A large number of risk factors have been documented and proposed for MI. A priori, 
we selected co-variates to include in the adjusted models based on the current 
evidence of association with MI and/or the exposure(s). Adjustment for potential 
confounding was applied in different steps allowing for clear interpretations of the 
results. We used the same strategy to control confounding for all studies, as outlined 
below. However, for study III with genotype as the primary exposure, we considered 
the more basic models as the most appropriate (model A1 and A2). All continuous 
variables were included in the models as restricted cubic splines with five knots. 
Model A1. Crude models were presented without adjustment for confounders, except 
for the pooled analyses including both women and men where we adjusted for sex. 
Large variations between the crude and adjusted models could indicate the 
importance of confounding.   
Model A2. In model A2, we adjusted for traditional epidemiological risk factors for MI, 
included the following variables: 
 Smoking habits, categorised as never, former or current (<15 g/day, 15-25 
g/day, >25 g/day) smokers 
 Physical activity (hours/week) of moderate to high intensity 
 Educational level, categorised as basic school (<7 years of education), 
higher education (8-10 years, >10 years) 
 Alcohol intake (g/day) 
 Body mass index (kg/m2) 
 Waist circumference (cm) 
 Menopausal status (pre- or post-menopausal) for women.  
In general, this model has a clear interpretation and reduces potential confounding by 
adjusting for important lifestyle and demographic determinants.   
Model B. In addition to the variables included in model A2, we applied a second layer 
of variables adjusting for medical history. Variables were self-reported history of 
physician-diagnosed disease and use of specific medications related to the diseases.  
 Hypertension and/or use of anti-hypertensive medications 
 Hypercholesterolaemia and/or use of lipid-lowering drugs 
 Diabetes mellitus (all types).  
These variables are normally considered important risk factors for MI and potential 
confounders. However, considering the broad range of mechanisms proposed for n-3 
PUFA, including effects on blood pressure, plasma lipids and inflammation, these co-
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variates may represent intermediate steps in causal pathways by which n-3 PUFA 
may affect the risk of MI. Thus, including these additional variables may introduce bias 
by eliminating the causal pathway through the mediators. However, the potential 
mediators are probably only affected by the exposure to a limited extent and residual 
confounding may be the implication if not including these variables, particularly since 
they represent some of the strongest risk factors for MI.  
Model C. Here, we included dietary variables in addition to the traditional risk factors 
from model A2. This implies adjustment for potential confounding from other aspects 
of the diet, but it may also introduce dietary patterns which are less relevant compared 
with an ordinary diet. For this reason, we limited the number of dietary co-variates to 
the most relevant ones based on known association with MI. Furthermore, variables 
were selected based on the nature of the exposure. E.g. when using specific fatty 
acids, we included co-variates at the level of specific nutrients, while complex whole 
food elements were used when evaluating fish intake. Thus, dietary co-variates 
reflected the nutritional level of the exposure. 
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CHAPTER 5. STUDIES 
This thesis is based on four studies that are included as published papers or 
manuscripts in the appendix. This section is meant to provide a short overview of the 
studies and present additional figures/tables which were not included in the final 
version of the manuscripts. For a more detailed description of the applied methods, 
please refer to "Chapter 4. Methods" or the full version of the manuscripts. 
Figure 5. Cohort selection process - overview of the four studies.
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5.1. STUDY I 
Aim 
In the first study we evaluated dietary intake of fish and the association with incident 
MI. Furthermore, fish consumption was sub-divided into fatty and lean fish, and 
intakes of total and individual marine n-3 PUFA were calculated. The main hypothesis 
was that fish intake would be inversely associated with MI, and this association would 
be stronger for fatty fish than for lean fish.   
Key methods 
The study was based on the Danish Diet, Cancer and Health study. Data for this study 
originated from detailed semi-quantitative food frequency questionnaires including 26 
specific questions regarding fish intake. Fish consumption was divided into fatty or 
lean fish based on the content of n-3 PUFA (more or less than 1g n-3 PUFA per 100g 
of fish) in the specific fish species. Furthermore, intake of total and specific n-3 PUFA 
was calculated based on Danish food composition tables. Data were analysed in a 
traditional cohort design using Cox proportional multivariate hazards models to 
evaluate the association between various measures of fish intake and incident MI. 
Main results 
A total of 3,089 cases of incident MI were identified and validated during a median 
follow-up time of 17 years. Baseline characteristics are reported in Table 3, p34 and 
the cohort selection process is illustrated in Figure 5, p33. After exclusions for missing 
co-variates 3,028 cases were included in the analyses. Fatty fish was inversely 
associated with incident MI for both men and women when comparing the highest 
quintile with the lowest (Table 4). For men, the association was modest with a 
HR=0.88 (95% CI: 0.77;1.00), and more pronounced for women with a HR=0.78 (95% 
CI: 0.63;0.96) after adjustments for potential confounding. Lean fish was not 
associated with the risk of incident MI.   
Limitations 
First of all, the study was based on a prospective cohort design with a thorough case 
validation and almost no loss to follow-up. We considered a few limitations. A frequent 
concern about data based on questionnaires is the risk of measurement error and bias 
and though we consider the questionnaires to be of high quality, we cannot rule out 
the potential of bias. One very important issue was the relatively long follow-up during 
which the diet was not re-evaluated. Thus, it is possible that the dietary habits, 
recorded at baseline, might change over time as well as other lifestyle and 
demographic data. This could potentially bias our results and limit our ability to control 
confounding. However, our study population was 50-64 years of age at baseline and 
middle-aged and elderly people are probably less likely to change their diet and 
lifestyle than young people. Indeed, a study on the general population of Denmark, 
showed that fish consumption was rather constant during 1995-2004 (119).     
MARINE N-3 FATTY ACIDS AND GENETIC VARIANTS IN THE 5-LIPOXYGENASE PATHWAY 
34
 
Main conclusions 
For both men and women, incident MI was inversely associated with dietary intake of 
fatty fish, while lean fish was not associated with MI. 
Table 4. Association between dietary fish consumption and incident MI 
Men 
 Model A1* Model A2** Model B*** Model C**** 
Fatty fish 
Q1 (0-8 g) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 
Q2 (>8-13 g) 0.88 (0.77;1.00) 0.89 (0.79;1.03) 0.90 (0.79;1.03) 0.91 (0.80;1.04) 
Q3 (>13-18 g) 0.84 (0.73;0.96) 0.89 (0.78;1.01) 0.89 (0.78;1.02) 0.90 (0.79;1.03) 
Q4 (>18-28 g) 0.82 (0.72;0.94) 0.90 (0.79;1.03) 0.90 (0.78;1.03) 0.92 (0.80;1.06) 
Q5 (>28 g) 0.83 (0.72;0.94) 0.91 (0.79;1.04) 0.88 (0.77;1.00) 0.93 (0.81;1.07) 
Lean fish 
Q1 (0-14 g) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 
Q2 (>14-21 g) 1.07 (0.94;1.23) 1.12 (0.98;1.29) 1.13 (0.99;1.29) 1.14 (1.00;1.31) 
Q3 (>21-28 g) 1.05 (0.92;1.21) 1.11 (0.97;1.27) 1.10 (0.96;1.26) 1.14 (0.99;1.30) 
Q4 (>28-39 g) 1.01 (0.89;1.16) 1.09 (0.95;1.25) 1.07 (0.94;1.23) 1.12 (0.97;1.29) 
Q5 (>39 g) 1.04 (0.91;1.19) 1.07 (0.93;1.23) 1.05 (0.91;1.20) 1.12 (0.97;1.29) 
Women 
 Model A1* Model A2** Model B*** Model C**** 
Fatty fish 
Q1 (0-6 g) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 
Q2 (>6-10 g) 0.86 (0.70;1.06) 0.95 (0.77;1.16) 0.95 (0.77;1.16) 0.96 (0.78;1.18) 
Q3 (>10-15 g) 0.85 (0.69;1.04) 0.96 (0.78;1.17) 0.93 (0.76;1.15) 0.98 (0.80;1.21) 
Q4 (>15-23 g) 0.90 (0.74;1.10) 1.07 (0.87;1.31) 1.04 (0.85;1.27) 1.11 (0.90;1.36) 
Q5 (>23 g) 0.69 (0.56;0.85) 0.83 (0.67;1.03) 0.78 (0.63;0.96) 0.86 (0.69;1.08) 
Lean fish 
Q1 (0-13 g) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 
Q2 (>13-18 g) 0.94 (0.77;1.16) 1.00 (0.82;1.23) 1.01 (0.82;1.24) 1.03 (0.84;1.27) 
Q3 (>18-24 g) 0.87 (0.71;1.07) 0.95 (0.77;1.17) 0.93 (0.76;1.15) 0.98 (0.79;1.21) 
Q4 (>24-33 g) 0.90 (0.73;1.10) 0.99 (0.81;1.22) 0.98 (0.80;1.21) 1.04 (0.84;1.29) 
Q5 (>33 g) 0.89 (0.72;1.09) 0.95 (0.77;1.16) 0.93 (0.75;1.14) 0.99 (0.79;1.24) 
Cox proportional hazard models for men and women separately, reported as hazard ratios with 
95% confidence intervals in parentheses. 
*Model A1: Crude analysis. 
**Model A2: Adjusted for traditional risk factors including: Smoking, body mass index, waist 
circumference, physical activity, alcohol intake, educational level, menopausal status(women). 
***Model B: Adjusted as model A2 with additional covariates: History of diabetes mellitus, 
hypertension and hypercholesterolaemia. 
****Model C: Adjusted as model A2 with additional dietary covariates: Total energy intake, 
intake of fruits and vegetables and intake of nuts. 
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5.2. STUDY II 
Aim 
In this study, we investigated the association between the content of total and 
individual marine n-3 PUFA in adipose tissue and incident MI. We hypothesised that 
total and individual n-3 PUFA would be inversely associated with incident MI.    
Key methods 
Using a case-cohort design, a randomly selected sub-cohort (n=3,500) was drawn 
within the Danish Diet, Cancer and Health study, to represent the entire cohort. Thus, 
the study cohort included cases of incident MI and the sub-cohort. Adipose tissue 
samples were collected at baseline and their composition was analysed by gas 
chromatography. Statistical analyses were performed using weighted Cox 
proportional multivariate hazard models. 
Main results 
Baseline characteristics are reported in Table 3, p34 and the cohort selection process 
is illustrated in Figure 5, p33. Notably, 421 subjects had missing adipose tissue 
biopsies and a total of 2,814 cases were included in the analyses. We examined the 
association of the three major marine n-3 PUFA (EPA, DPA and DHA) with incident 
MI (Table 5). In both men and women we found an inverse relationship between the 
content of EPA in adipose tissue and MI when comparing the highest and lowest 
exposure quintile. The association did not change substantially after multivariate 
adjustment and remained statistically significant with a HR of 0.76 (95% CI: 0.60;0.97) 
for men and a HR of 0.70 (95% CI: 0.49;0.99) for women when adjustments were 
applied (model B). For men, the same tendency was observed for DHA with a negative 
association in the fourth and fifth quintile. However, multivariate adjustment for 
traditional risk factors for MI attenuated the association, and adjusted analyses were 
borderline significant. In women we found no consistent association between DHA 
content and MI. Further, no consistent associations between DPA content and MI 
were detected for neither men nor women. In addition to the analyses of quintiles, 
adipose tissue n-3 PUFA were evaluated continuously as restricted cubic splines with 
three knots (Figure 6) indicating an inverse association between EPA and MI, as 
observed for the quintiles.  
Limitations 
This study used a nested case-cohort design, which implies that a sub-sample of the 
whole cohort was drawn to represent the cohort. Thus, the sample size for this study 
was smaller than for Study I. However, this issue was addressed by assigning weights 
to each non-case from the sub-cohort and implementing this weighting scheme in the 
Cox regression. Furthermore, the sub-cohort resembled the cohort on all baseline 
parameters (Table 3, p34). Compared with questionnaires, adipose tissue fatty acids 
have the advantage, as a biomarker, of being an objective measure of the exposure, 
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and as such less prone to bias. Importantly, it was evident from correlations between 
dietary intake of n-3 PUFA and adipose tissue content (Table 6), that adipose tissue 
was only moderately correlated with dietary intake, and adipose tissue n-3 PUFA may 
more truly reflect the endogenous exposure to these fatty acids than their dietary 
intake. Furthermore, we used the relative proportion of fatty acids and not their 
absolute concentration, which is conventional but might be considered a weakness.     
Main conclusions 
The content of EPA was inversely associated with incident MI in both men and women, 
and while the same tendency was observed for DHA, associations were only 
borderline significant. DPA was not associated with incident MI. 
Table 5. Association between the adipose tissue content of marine n-3 PUFA and 
incident MI. 
Men 
 Model A1* Model A2** Model B*** Model C**** 
Content of EPA (%) 
Q1 (0.00-0.07) 1 (ref)  1 (ref)  1 (ref)  1 (ref)  
Q2 (>0.07-0.09) 1.01 (0.83;1.23) 0.99 (0.80;1.23) 1.00 (0.80;1.24) 0.96 (0.77;1.20) 
Q3 (>0.09-0.11) 0.83 (0.68;1.02) 0.80 (0.64;1.01) 0.82 (0.65;1.04) 0.77 (0.60;0.98) 
Q4 (>0.11-0.14) 0.93 (0.76;1.14) 0.96 (0.77;1.19) 0.92 (0.74;1.16) 0.86 (0.66;1.10) 
Q5 (>0.14) 0.74 (0.60;0.92) 0.79 (0.62;1.00) 0.76 (0.60;0.97) 0.65 (0.47;0.90) 
Content of DPA (%) 
Q1 (0.00-0.21) 1 (ref)  1 (ref)  1 (ref)  1 (ref)  
Q2 (>0.21-0.24) 1.21 (0.99;1.49) 1.21 (0.98;1.51) 1.22 (0.98;1.53) 1.26 (1.00;1.57) 
Q3 (>0.24-0.28) 1.10 (0.89;1.35) 1.16 (0.93;1.44) 1.16 (0.92;1.45) 1.19 (0.93;1.52) 
Q4 (>0.28-0.33) 1.09 (0.89;1.34) 1.12 (0.89;1.41) 1.08 (0.86;1.37) 1.17 (0.90;1.52) 
Q5 (>0.33) 1.03 (0.84;1.27) 1.09 (0.87;1.38) 1.00 (0.79;1.27) 1.14 (0.84;1.54) 
Content of DHA (%) 
Q1 (0.00-0.17) 1 (ref)  1 (ref)  1 (ref)  1 (ref)  
Q2 (>0.17-0.22) 1.00 (0.82;1.23) 0.95 (0.77;1.18) 0.92 (0.74;1.15) 0.95 (0.76;1.20) 
Q3 (>0.22-0.27) 0.96 (0.78;1.18) 0.99 (0.79;1.23) 0.95 (0.76;1.19) 0.95 (0.74;1.21) 
Q4 (>0.27-0.35) 0.80 (0.65;0.99) 0.88 (0.71;1.10) 0.88 (0.70;1.10) 0.85 (0.63;1.06) 
Q5 (>0.35) 0.79 (0.64;0.97) 0.88 (0.70;1.10) 0.81 (0.64;1.01) 0.77 (0.56;1.06) 
Women 
 Model A1* Model A2** Model B*** Model C**** 
Content of EPA (%) 
Q1 (0.00-0.06) 1 (ref)  1 (ref)  1 (ref)  1 (ref)  
Q2 (>0.06-0.08) 1.00 (0.76;1.31) 0.97 (0.71;1.31) 0.97 (0.71;1.32) 0.93 (0.68;1.28) 
Q3 (>0.08-0.10) 1.11 (0.83;1.49) 1.14 (0.82;1.58) 1.10 (0.78;1.54) 1.06 (0.74;1.50) 
Q4 (>0.10-0.13) 0.96 (0.74;1.25) 1.00 (0.74;1.35) 0.99 (0.72;1.34) 0.83 (0.58;1.19) 
Q5 (>0.13) 0.69 (0.52;0.92) 0.80 (0.57;1.11) 0.70 (0.49;0.99) 0.59 (0.37;0.92) 
Content of DPA (%) 
Q1 (0.00-0.22) 1 (ref)  1 (ref)  1 (ref)  1 (ref)  
Q2 (>0.22-0.26) 1.18 (0.89;1.57) 1.19 (0.86;1.64) 1.15 (0.83;1.60) 1.24 (0.89;1.73) 
Q3 (>0.26-0.31) 1.12 (0.85;1.49) 1.09 (0.78;1.51) 1.07 (0.76;1.50) 1.16 (0.79;1.68) 
Q4 (>0.31-0.36) 1.35 (1.02;1.80) 1.41 (1.00;1.97) 1.35 (0.96;1.89) 1.45 (0.98;2.14) 
Q5 (>0.36) 1.17 (0.88;1.54) 1.16 (0.83;1.63) 1.05 (0.74;1.48) 1.15 (0.73;1.82) 
Content of DHA (%) 
Q1 (0.00-0.19) 1 (ref)  1 (ref)  1 (ref)  1 (ref)  
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Q2 (>0.19-0.25) 0.78 (0.59;1.03) 0.76 (0.56;1.04) 0.77 (0.56;1.05) 0.71 (0.52;0.98) 
Q3 (>0.25-0.30) 0.91 (0.69;1.21) 0.96 (0.69;1.33) 0.97 (0.69;1.36) 0.90 (0.63;1.30) 
Q4 (>0.30-0.39) 1.05 (0.80;1.38) 1.11 (0.81;1.53) 1.10 (0.80;1.52) 0.97 (0.66;1.41) 
Q5 (>0.39) 0.68 (0.51;0.91) 0.88 (0.63;1.22) 0.81 (0.57;1.15) 0.74 (0.46;1.20) 
Abbreviations: EPA, Eicosapentaenoic acid; DPA, Docosapentaenoic acid; DHA, 
Docosahexaenoic acid. 
Cox proportional hazard models for men and women separately, reported as hazard ratios with 
95% confidence intervals in parenthesis. 
*Model A1: Crude analysis. 
**Model A2: Adjusted for traditional risk factors including: Smoking, body mass index, waist 
circumference, physical activity, alcohol intake, educational level, menopausal status(women). 
***Model B: Adjusted as model A2 with additional covariates: History of diabetes mellitus, 
hypertension and hypercholesterolaemia.  
****Model C: Adjusted as model A2 with additional covariates: Adipose tissue content of total 
saturated, monounsaturated and polyunsaturated (excl. marine n-3 PUFA) fatty acids and 
dietary fiber. 
 
Table 6. Correlations between dietary intake and adipose tissue n-3 PUFA. 
Men 
 Adipose tissue Dietary intake 
 EPA DPA DHA EPA DPA DHA 
Adipose tissue 
EPA 1      
DPA 0.74 1     
DHA 0.86 0.82 1    
Dietary intake 
EPA 0.37 0.29 0.41 1   
DPA 0.17 0.15 0.21 0.77 1  
DHA 0.33 0.26 0.37 0.97 0.82 1 
Women 
 Adipose tissue Dietary intake 
 EPA DPA DHA EPA DPA DHA 
Adipose tissue 
EPA 1      
DPA 0.74 1     
DHA 0.84 0.79 1    
Dietary intake 
EPA 0.33 0.23 0.37 1   
DPA 0.17 0.11 0.21 0.76 1  
DHA 0.30 0.20 0.34 0.97 0.83 1 
Abbreviations: EPA, Eicosapentaenoic acid; DPA, Docosapentaenoic acid; DHA, 
Docosahexaenoic acid. 
Pearson's correlation coefficients presented separately for men and women. Correlations 
between adipose tissue n-3 fatty acids and their corresponding dietary n-3 fatty acids are 
marked by bold figures. 
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Figure 6. Spline curves illustrating the association between the adipose tissue content 
of specific n-3 PUFA and incident MI. Restricted cubic spline curves with three knots 
showing hazard ratios with 95% confidence interval (grey area) for the association between 
incident myocardial infarction (MI) and adipose tissue content of (A) EPA, (B) DPA and (C) 
DHA. Results are presented for men and women separately with the median content as 
reference. Vertical lines indicate quintiles of fatty acid content.   
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5.3. STUDY III 
Aim 
In the third study we investigated four candidate genes in the 5-LOX pathway. Our 
aim was to examine associations between individual polymorphisms and inferred 
haplotypes with incident MI. The main hypothesis was that genetic variants would be 
associated with MI.  
Key methods 
In a nested case-cohort study design based on the Diet Cancer and Health study, we 
conducted a genetic association study examining four candidate genes in the 5-LOX 
pathway (ALOX-5, FLAP, LTA4-H and LTC4-S). A randomly selected sub-cohort 
(n=3,000) was drawn to represent the cohort. We selected 22 SNPs and a tandem-
repeat polymorphism primarily based on previous association with atherosclerotic 
disease. SNPs were genotyped by LGC Genomics, UK, using the KASPTM genotyping 
assay, while the tandem repeat was genotyped by sequencing technique. Measures 
of association were assessed by Cox proportional hazard models using a weighting 
scheme to account for the size of the nested sub-cohort. Haplotypes were inferred 
using PHASE 2.1, and weights were assigned to each subject based on the probability 
of each pair of haplotypes derived from PHASE.       
Main results 
In total, 2,876 cases were included in the analyses after exclusions (Figure 5, p33). 
Analysing the tandem repeat polymorphism in ALOX-5 (rs59439148) we found a 
positive association with MI in men, while no association was detected in women. The 
pooled estimates showed the same pattern as for men (Table 7). A number of SNPs 
were associated with incident MI when comparing homozygotes carriers of the minor 
allele with homozygotes for the major allele. In FLAP we found two markers 
(rs9551963 and rs17222842) that were negatively associated with MI, while in LTA4-
H, rs2247570 was positively associated with MI when comparing homozygotes for the 
minor allele with homozygotes for the major allele (Table 7). Previously reported 
haplotypes were not associated with MI in our population.   
Limitations 
The present study was designed as a candidate gene study which has the clear 
advantage of providing a high power to detect genotype-phenotype associations with 
a relatively limited sample size compared with genome wide association studies. Our 
study were limited by only investigating the four candidate genes selected for the 
study, while there might be other genes involved in regulating the 5-LOX pathway. A 
frequent problem in genetic association studies is the number of statistical tests 
performed, which may increase the chance of type I errors. This was addressed by 
limiting the number of SNP markers for the current study, by testing only one genetic 
model of inheritance and testing only one crude and one adjusted model. 
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Main conclusions 
A number of individual SNPs and the tandem repeat polymorphism were associated 
with incident MI. However, associations were modest and haplotype associations did 
not reveal any clear associations with the phenotype. Collectively, the study suggests 
that the 5-LOX pathway may play a role for the risk of incident MI.  
Table 7. Polymorphisms associated with incident MI. 
SNP Genotype Model A1* Model A2** 
ALOX-5 
rs59439148 W/W 1 (ref)  1 (ref)  
 W/V 0.94 (0.83;1.06) 0.96 (0.84;1.10) 
 V/V 1.23 (0.89;1.71) 1.35 (0.96;1.90) 
FLAP 
rs9551963 C/C 1 (ref)  1 (ref)  
 C/A 0.86 (0.75;0.98)a 0.83 (0.72;0.96)a 
 A/A 0.85 (0.73;0.99)a 0.80 (0.68;0.95)a 
rs17222842 G/G 1 (ref)  1 (ref)  
 G/A 0.97 (0.85;1.12) 0.94 (0.81;1.10) 
 A/A 0.40 (0.22;0.73)a 0.44 (0.24;0.82)a 
LTA4-H 
rs2247570 A/A 1 (ref)  1 (ref)  
 A/G 1.00 (0.90;1.13) 1.00 (0.88;1.13) 
 G/G 1.23 (1.01;1.51)a 1.28 (1.03;1.59)a 
Abbreviations: SNP, Single nucleotide polymorphism; ALOX-5, Arachidonate 5-lipoxygenase; 
FLAP, 5-lipoxygenase activating protein; LTC4-S, Leukotriene C4 synthase; LTA4-H, 
Leukotriene A4 hydroxylase. 
The table displays hazard ratios from weighted Cox proportional hazard models. Alleles 
correspond to the positive DNA-strand according to dbSNP, human assembly GRCh38.p2. 
*Model A1: Crude analyses adjusted for sex. 
**Model A2: Adjusted analyses including sex, smoking status, educational level, physical activity, 
BMI, waist circumferrence and alcohol consumption. 
ap-value < 0.05, not adjusted for multiple comparisons. 
 
5.4. STUDY IV 
Aim 
This study investigated possible interaction between substrates for the ALOX-5 
enzyme (EPA and AA) and the tandem repeat polymorphism, located in the promotor 
region of the ALOX-5 gene, in relation to incident MI. We hypothesised that the effect 
of the polymorphism would be modulated by the content of EPA and AA in adipose 
tissue, where EPA would blunt the effect of the variant genotype while AA would 
augment the effect.  
Key methods 
To evaluate interaction between genotype and ALOX-5 substrates we used data from 
DNA samples and adipose tissue biopsies. The tandem polymorphism was genotyped 
by multi-titre plate sequencing determining the number of tandem repeats for each 
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allele and adipose tissue content was determined by gas chromatography. A case-
cohort design was used to analyse data. Measures of association were assessed 
using Cox proportional hazards models. Potential interaction between genotype and 
adipose tissue EPA or AA was investigated by cross-tabulating HRs for genotype by 
quintiles of EPA or AA. Furthermore, we calculated the relative excess risk due to 
interaction (RERI) to determine biological interaction quantitatively.    
Main results 
The study included 2,680 cases after exclusion of participants with missing data on 
adipose tissue biopsies and/or genotype information (Figure 5, p33). Overall, the 
results indicated a higher risk of MI for homozygous carriers of the variant alleles 
compared to carriers of the wildtype. When cross-tabulating the genotype by quintiles 
of EPA or AA content in adipose tissue (Table 8), we found the highest risk for MI 
when comparing the lowest quintile group of EPA for homozygous carriers of the 
variants with the reference group (HR=2.15, 95% CI: 0.91;5.09), while for AA, the 
highest risk of MI was found when comparing the highest quintile stratum of AA 
content for homozygotes for the variants compared to the reference (HR=3.02, 95% 
CI: 1.41;6;44). RERI were calculated to assess interaction on an additive scale, and 
measures of association were not statistically significant.          
Limitations 
Despite a relatively large number of cases and sub-cohort members that had 
information on both genotype and adipose tissue fatty acids, the number of 
homozygous carriers was limited. This made assessments for interaction challenging, 
when cross-tabulating genotype by quintiles of EPA and AA content. Furthermore, 
sex-stratified analyses did not yield meaningful results for women because of the 
limited number of female cases. This raises the concern that the study was 
underpowered to detect possible interaction by adipose tissue EPA and AA. 
Main conclusions 
Results indicated that associations between genotype and incident MI were 
modulated by EPA and AA, where EPA attenuated the effect and AA exacerbated the 
effect, albeit analyses of interaction by RERI were not statistically significant.  
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CHAPTER 6. DISCUSSION 
The overall aim of the thesis was to investigate whether fish consumption and marine 
n-3 PUFA were associated with incident MI. Furthermore, genetic variants in the 5-
LOX pathway was examined and the interaction between a functional polymorphism 
in the ALOX-5 gene and fatty acids substrates for the pathway was explored. We 
investigated the dietary consumption of fish based on food frequency questionnaires 
(Study I), and next, the adipose tissue content of major marine n-3 PUFA was 
evaluated (Study II). The studies supported an inverse association with MI for fatty 
fish and adipose tissue content of EPA. Next, we conducted a candidate gene study, 
exploring genetic variants in the 5-LOX pathway (Study III). Individual SNPs were 
associated with MI, but in general associations were modest, and previously reported 
haplotypes were not associated with MI. In Study IV, a functional tandem repeat in 
ALOX-5 was studied, examining interaction between the polymorphism and adipose 
tissue content of EPA or AA (substrates for the 5-LOX pathway). The data indicated 
that the content of EPA and AA modified the risk imposed by the variant genotype. 
However, quantitative measures of interaction were, not statistically significant.      
Evaluating dietary fish intake – biomarkers vs. dietary questionnaires 
The studies included in this thesis were observational studies based on the Danish 
prospective cohort study, the Diet, Cancer and Health Study. Essential issues in 
observational studies relate to how outcome is assessed, which was explained in 
detail earlier, "Chapter 4. Methods". Importantly, Joensen et al. (113) validated 
diagnoses of MI from national registries through 2003, and an algorithm was 
established to validate new diagnoses from January 2004 and forth, which was used 
in the present thesis.      
Another important issue was how to evaluate the exposure. The intake of marine n-3 
PUFA was evaluated by two different approaches. First, fish intake was assessed 
using semi-quantitative food frequency questionnaires, and secondly, adipose tissue 
content of marine n-3 PUFA, a long-term biomarker of the dietary intake, was 
determined. 
The dietary questionnaire was detailed, including 26 specific questions concerning 
intake of fish and food products containing fish, thereby allowing us to differentiate 
between types of fish and to categorise fish intake according to the relative amount of 
n-3 PUFA. Furthermore, the questionnaire had been carefully developed and 
validated by comparison with two times seven days weighed dietary recordings 
(111,120). However, some concerns remain. First of all, it may be difficult for subjects 
to recall and make an accurate assessment of their average food intake. This 
becomes even more difficult as the period of recall becomes longer, and periodical 
variations in food consumption are likely to be reflected in the dietary questionnaire 
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although participants were asked to report their average intake of the food items 
during the last 12 months. Apart from this general issue, a number of innate problems 
may be related to dietary assessment from questionnaires, including reporting of 
complex food items, errors in calculating more specific food items from food 
composition tables, systematic over- / under-reporting of specific food items and errors 
in estimating correct portion sizes. Importantly, the questionnaire was filled-in at 
baseline with no specific focus on the exposure and before participants had any 
knowledge about future disease. Thus, potential measurement error including 
information bias was unlikely to be differentiated, and possible random error caused 
by imprecise estimation of the individual food intake would be, at least partly, 
compensated by the size of the cohort.        
Biomarkers of n-3 PUFA intake represents an objective measure whereas dietary 
recordings are prone to subjectivity, and specific fatty acids can be determined with 
high precision. We used adipose tissue content of marine n-3 PUFA as an objective 
measure of n-3 PUFA, which is a widely used biomarker, reflecting long-term 
exposure to these fatty acids (21). Thus, based on the long half-life of white adipose 
tissue cells of approximately 600 days, it has been suggested that adipose tissue may 
reflect the average dietary intake during the last 1-3 years (121). However, the fatty 
acid composition of adipose tissue is dependent, not only on the dietary intake, but 
also on the uptake and release from adipose tissue as well as their metabolism. 
Notably, marine n-3 PUFA can be synthesised endogenously from the conversion of 
ALA, although only to a limited extent (12,122). However, considering that the dietary 
intake of ALA often is considerably higher than the intake of marine n-3 PUFA, the 
amount of long-chained n-3 PUFA derived from ALA might not be trivial. Therefore, 
adipose tissue content may more truly reflect the endogenous exposure to n-3 PUFA 
and, as a consequence of the dependency on endogenous processes, may reflect the 
dietary intake less precisely. Indeed, the correlations between dietary intake and 
adipose tissue content of n-3 PUFA were modest (Table 6, p39). However, the 
endogenous exposure may be a valuable measure of exposure compared to the true 
dietary exposure, depending on the specific questions asked (123–125). Taken 
together, dietary questionnaires and adipose tissue biopsies have their individual 
advantages and disadvantages, and as such, they should be regarded as 
complementary in evaluating the true exposure to n-3 PUFA. 
Association of fish consumption and adipose tissue content of marine n-3 
PUFA with incident MI 
The main findings from Study I & II were that dietary intake of fatty fish was inversely 
related to incident MI. In contrast, no association could be demonstrated between lean 
fish intake and MI. Furthermore, the content of EPA in adipose tissue was negatively 
associated with incident MI. The same tendency was observed for DHA (non-
significant), whereas DPA was not associated with incident MI. 
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In the Diet, Cancer and Health cohort, two earlier studies had been conducted 
examining the association of fish intake and adipose tissue marine n-3 PUFA content 
in participants with ACS (35,36). Thus, Bjerregaard et al. (36) found an inverse 
relationship between intake of fatty fish and ACS in men, suggesting a HR of 0.68 
from eating a moderate to high amount of fatty fish. Another study on adipose tissue 
n-3 PUFA demonstrated a lower risk of ACS in men with a high content of marine n-3 
PUFA (35). Findings in women were non-significant without a concise pattern for both 
studies. In Study I we also demonstrated a negative association in men, but the 
associations were somewhat attenuated during follow-up, and our results suggested 
a modest HR of 0.88, when comparing the lowest and the highest quintile in men. In 
light of these inconsistencies, we performed additional analyses dividing the study 
period according to the earlier studies and found the same associations as previously 
observed. However, it is not unusual to observe a weakening of the associations in 
cohort studies during long follow-up periods, which may be explained by a decline in 
the preventive potential of the exposure, simply because the subjects that had a high 
effect of n-3 PUFA intake are the same subjects that have a high risk of experiencing 
an event (MI). Furthermore, as a result of higher age among the participants during 
longer follow-up, the relative risk ratio for experiencing an MI may decrease between 
the group with high fish intake and low fish intake because age becomes a more 
dominant risk factor. Other explanations, such as cohort-wide changes in lifestyle and 
standard medical treatment towards a more heart healthy profile, may help explain 
our findings as well. In women, Study I & II showed a more consistent pattern 
compared to the earlier studies and suggested a HR of 0.78 when comparing the 
highest quintile of fatty fish with the lowest. Our studies included a considerably larger 
number of cases (n=3,089) compared to the previous dietary study (n=1,122), and 
particularly with regard to the analyses on adipose tissue biopsies (n=1,012). Notably, 
the number of female cases was larger providing considerably more strength to 
explore the associations in both men and women. 
Epidemiological studies have generally provided evidence for a protective role of fish 
consumption (31–38,40), supported by secondary intervention trials (42,43,126) 
associating fish intake and fish oil supplements with a lower risk of CHD and sudden 
cardiac death. Summarising data from prospective cohort studies, He et al. conducted 
a meta-analysis in 2004, suggesting that 1 fish serving/week was associated with a 
15% lower risk of fatal CHD, and 2-4 servings/week with 23% lower risk. These earlier 
trials lead to the conclusion among many researchers and scientific communities that 
intake of fish and fish oil supplements reduces the risk of CHD. Consequently, both 
the European Society of Cardiology (46) and the American Heart Association (45) 
recommend a daily intake of marine n-3 PUFA of 1 g/day for the secondary prevention 
of CHD. However, more recent trials have come to question the beneficial effects from 
dietary n-3 PUFA supplements on CHD (47–49). Several reasons might explain these 
findings (127). First of all, methodological variations, different populations and 
different interventions might explain some of the differences. Notably, recent trials 
were all conducted in populations with aggressive background medical therapy, 
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including lipid lowering, anti-hypertensive and anti-platelet therapy. In support of this 
notion, post hoc analyses from the Alpha Omega Trial found no effect of n-3 PUFA 
supplements in statin users, but in contrast, n-3 PUFA supplementation was 
associated with a 50% reduction in major CVD events among non-statin users (128). 
Further, the beneficial effect of n-3 PUFA in earlier trials was mainly reported for fatal 
CHD, while recent trials have focused on non-fatal or composite endpoints for CHD. 
Finally, the background dietary fish intake was generally higher in recent trials in 
accordance with rising public awareness of a healthy lifestyle. 
In line with this, a recent meta-analysis (51) of secondary prevention trials reported a 
modest effect of marine n-3 PUFA on cardiac death (RR=0.91), sudden death 
(RR=0.87) and MI (RR=0.89). Moreover, associations were borderline significant, and 
the authors concluded that there was insufficient support for recommending fish oil 
supplements and fish intake for the secondary prevention of CVD. Mozaffarian et al. 
(52) also reviewed the evidence for n-3 PUFA and presented a combined meta-
analysis, including both observational studies and randomised controlled trials, 
suggesting a beneficial effect of n-3 PUFA intake on various CVD endpoints. Most 
recently, another meta-analysis presented pooled estimates from 19 cohort studies 
using a variety of biomarkers for n-3 PUFA and found a modest relative risk reduction 
of fatal CHD events of around 9% for various n-3 PUFA (53). Taken together, recent 
meta-analyses have reported a more modest effect of marine n-3 PUFA in the 
prevention of CVD (52,53),  and while individual differences between the meta-
analyses may be explained by the type of trials included, different endpoints among 
other differences in study design, there remains a discrepancy between most of the 
earlier trials and more recent trials examining n-3 PUFA and CVD. Where earlier trials, 
more convincingly, reported a beneficial effect on the prevention of CVD, and CHD in 
particular, some of the more recent studies have been inconclusive or neutral. The 
recent studies have stimulated renewed interest in n-3 PUFA, and dietary 
recommendations regarding fish consumption and fish oil supplementation in CVD 
prevention are currently being debated. 
Association of genetic polymorphisms in the 5-LOX pathway with incident MI 
To explore associations between genetic polymorphisms in the 5-LOX pathway and 
MI we conducted a candidate gene study examining the four genes encoding key 
enzymes in the pathway (Study III). A number of individual SNPs were associated with 
MI. However, associations were modest, and most of the associations were not 
statistically significant when applying corrections for multiple comparisons.  
A number of earlier genetic association studies have examined the association 
between polymorphisms in the 5-LOX pathway and various cardiovascular endpoints 
including ischemic stroke and CHD, as earlier reviewed. The following is a discussion 
of the evidence for each candidate gene and our results.  
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In ALOX-5 the tandem repeat polymorphism, rs59439148, was first found to be 
associated with higher intima-media thickness (88), a marker of atherosclerosis, but 
replication studies on cases with CHD, have been conflicting. Importantly, two 
independent studies in MI patients of Northern European origin (genetically close 
related to our population) did not find any association between variant alleles and MI 
(90,91). Another study, including a mixed population of Caucasians and African-
Americans, reported a positive association in African-Americans but not in 
Caucasians (92). In Study III, we found a positive association between homozygous 
carriers of the variant alleles and MI, but the association was only significant in men, 
while there was no association among women. Other SNPs have been explored in 
ALOX-5 (92,94), but only rs59439148 and SNPs linked to this polymorphism have 
been associated with atherosclerosis and atherothrombotic disease.  
In FLAP, the deCODE investigators identified two haplotypes (Hap-A and Hap-B), that 
were associated with risk of MI and/or ischemic stroke in three independent 
populations of Caucasians (95,96). Although, we could not confirm the association 
between previously defined haplotypes and MI in our population, we found two 
individual SNPs within the haplotype blocks that were associated with MI when 
comparing homozygous carriers of the minor allele with homozygotes for the major 
allele (rs9551963 and rs17222842). Other studies have investigated the SNPs and 
haplotypes within FLAP, but again results have been conflicting (92,94,98–104), and 
no consensus has been established in favour of a certain SNP or possible functional 
polymorphism.   
In LTA4-H, we analysed ten SNPs covering a haplotype block as previously described 
by the deCODE investigators (97). As for FLAP, we found some of the individual SNPs 
to be associated with incident MI, but the previously reported haplotype (Hap-K) was 
not associated with MI in our population.  
To further investigate haplotype associations, and potentially identify new and unique 
haplotypes for our cohort, we performed a global haplotype analysis for FLAP and 
LTA4-H SNPs. In these analyses, we included all common haplotypes (minor allele 
frequency > 0.01) inferred to our cohort in a multivariate model using the most 
common haplotype as the reference haplotype. By this method we found sporadic 
associations between haplotypes and incident MI, but the associations were modest. 
In conclusion, genetic association studies provide some evidence of a link between 
the 5-LOX pathway and atherosclerotic disease, which is supported by Study III. 
However, despite a number of studies performed, it has not been possible to 
consistently replicate initial findings and confirm the associations of specific 
polymorphism in most of the candidate genes. Genetic association studies are highly 
dependent on functional studies to establish causality and elucidate the biological 
significance of a polymorphism. In this respect, rs59439148 is the best documented 
polymorphism included in our study (76,89,129). Apart from this, Hap-A was 
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associated with a higher production of 4-series leukotrienes (95), indicating enhanced 
enzymatic activity from carrying this haplotype. Interestingly, several large genome 
wide association studies have been conducted since the deCODE studies, and none 
of these have pointed towards the 5-LOX pathway as being of major importance in 
CHD (130,131). These inconsistencies have led some authors to investigated the 
possibility that substrates of the 5-LOX pathway might interact with genetic variants in 
a complex environment where the effect of the genetic variant is dependent on 
substrate availability (88,89,105,106). Other authors have suggested that a “pathway 
approach” may be more appropriate, taking into account that each step of the 5-LOX 
pathway may influence the outcome all together. For instance, Crosslin et al. (104) 
examined how the expression of 5-LOX genes depended on the genotype of 
rs10507391, while another study found significant gene-gene interaction between a 
selected SNP from each of three 5-LOX genes (109). Aspects of gene-gene 
interactions were not explored during the work of this thesis.  
Refining the question – diet X gene interaction 
In Study IV we examined possible interaction between ALOX-5 substrates and the 
tandem repeat rs59439148. Cross-tabulation of genotype by quintiles of EPA or AA 
content indicated a higher risk of MI for carriers of two variant alleles as reported in 
Study III. While the association between genotype and MI was augmented by a higher 
content of AA, the opposite was observed for EPA, although interaction was not 
statistically significant when assessed quantitatively by calculating RERI. 
Dwyer et. al (88), were the first to associate the ALOX-5 tandem polymorphism with 
atherosclerosis traits, and also the first group to suggest interaction between dietary 
intake of 5-LOX substrates and the polymorphism. They found AA and marine n-3 
PUFA to modulate the association of variant genotypes with carotid intima-media 
thickness in opposite directions, which was in line with our findings. Later, the same 
group performed a larger study on Costa Ricans, including 1885 cases of MI (89). 
While the study showed no overall association of the variant genotype, subjects with 
a high intake of AA had a significantly higher risk of MI when the variant genotype was 
present indicating interaction between AA intake and genotype. In contrast, no 
interaction was detected for marine n-3 PUFA. Both studies used dietary 
questionnaires to assess the intake of fatty acids, while our study used adipose tissue 
content as a biomarker reflecting long-term dietary intake and more precisely the 
endogenous exposure to the respective fatty acids. 
Taken together, Study IV, along with other studies suggests that the association 
between the ALOX-5 tandem repeat polymorphism and atherothrombotic disease is 
modified by substrate availability, and this may be an important aspect to consider 
when evaluating the association between genetic variants in the 5-LOX pathway and 
multifactorial disorders. During the work of this thesis, we did not explore diet-gene 
interaction in other candidate genes from the 5-LOX pathway, but interestingly, Zhao 
et al recently reported significant diet-gene interaction between a haplotype in LTA4-
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H (Hap-E) and dietary intake of n-3 and n-6 PUFA (105,106). Therefore, it might be 
relevant to look for diet-gene interaction in other candidate genes of the 5-LOX 
pathway, which may help explain the heterogeneous results obtained from genetic 
association studies.     
Mechanistic evidence linking marine n-3 PUFA and the 5-LOX pathway to 
atherothrombotic disease  
The current thesis is based on prospective cohort studies, and this is important to 
keep in mind when discussing mechanistic aspects. Thus, the mechanisms by which 
n-3 PUFA influence the risk of MI in Study I & II are speculative.  
Seafood may contain several components apart from n-3 PUFA, e.g. selenium, 
vitamin D, iodine and peptides, which might contribute to possible health benefits 
including possible effect on CVD (132). However, Study I suggested that the content 
of n-3 PUFA is important since only fatty fish and not lean or total fish intake was 
associated with incident MI. Furthermore, we examined individual marine n-3 PUFA 
in Study II, and these analyses suggested that EPA might play a more important role 
than DHA and DPA. Few intervention trials have examined the effect of individual 
marine n-3 PUFA, as most intervention trials have examined a combination of EPA 
and DHA since these are found together in seafood. However, one large intervention 
trial in a Japanese population used a supplement of purified EPA and found a 
significant reduction in major cardiovascular events, suggesting cardioprotective 
effects of EPA independently of other marine n-3 PUFA (126). Thus, it has been 
suggested that individual marine n-3 PUFA have both shared and important 
differential effects (133). 
Several mechanisms have been suggested to explain the cardio-protective properties 
attributed to marine n-3 PUFA in general. N-3 PUFA are incorporated into cell 
membrane phospholipids, where they may affect membrane function, cell signalling, 
arrhythmic properties, and a variety of other processes (14,65,134). These 
mechanisms may explain a possible antithrombotic (126,135,136) and/or 
antiarrhythmic (44,60,61,137) effect of marine n-3 PUFA that may reduce risk of CHD. 
In addition, anti-inflammatory properties have been reported (11,134,138), possibly 
inferring a stabilising effect of marine n-3 PUFA on human atherosclerotic plaques 
(62,67) that may decrease the risk of plaque rupture and thus CHD events. Finally, 
marine n-3 PUFA also lower plasma triglycerides (139), increase serum adiponectine 
(140,141), impair platelet and leukocyte reactivity, lower heart rate, and may slightly 
reduce blood pressure (11,14,63,65). 
One of the key mechanisms linking the 5-LOX pathway to the development of 
atherosclerosis may be attributed to the formation of leukotrienes and their pro-
inflammatory properties. Leukotrienes increase vascular permeability and act as 
potent chemo-attractants among other pro-inflammatory functions (69,70,74). 
Furthermore, a high expression of multiple 5-LOX enzymes has been found in human 
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atherosclerotic plaques and levels of the same enzymes have been linked to the stage 
of plaque development (82,83). Genetic association studies have also provided 
evidence of a link between the 5-LOX pathway and atherosclerotic disease as 
discussed earlier. Especially, the ALOX-5 tandem repeat polymorphism has 
demonstrated a functional relationship between genetic variants leading to altered 
enzymatic activity and ultimately affecting the risk of MI. In this regard, Study III adds 
to the body of evidence in support of this hypothesis.  
The functional relationship between n-3 PUFA and the 5-LOX pathway is evident as 
EPA is a substrate for the 5-LOX enzymes competing with AA (11,14). Importantly, 
EPA generally leads to the formation of far less pro-inflammatory leukotrienes 
compared with leukotrienes derived from AA (72,73). In accordance with this, it has 
been proposed that anti-inflammatory properties of n-3 PUFA intake may be explained 
by the incorporation of n-3 PUFA, mainly EPA, at the expense of AA in cell membrane 
phospholipids, thereby causing a shift in the leukotriene production towards less pro-
inflammatory leukotrienes among other effects (142). In Study IV, our results indicated 
an interaction (although not statistically significant) between fatty acid substrates for 
the 5-LOX enzymes and the ALOX-5 tandem repeat polymorphism (rs59439148), 
which is in line with the hypothesis that the differential roles of marine n-3 PUFA and 
AA in atherosclerotic disease states may, at least partly, be explained by the formation 
of less pro-inflammatory leukotrienes derived from EPA compared with AA. In this 
respect, the study provides the characteristics of a Mendelian randomisation study 
adding mechanistic evidence for a role of EPA and AA in MI through the 5-LOX 
system.  
General comments on the study design and generalisability 
Specific limitations related to the individual studies are mentioned in "Chapter 5. 
Studies" and in the papers included in the appendix. Here, a few general thoughts on 
the prospective design and generalisability will be provided. 
First of all, we used an observational design. The Diet, Cancer and Health study is a 
prospective cohort study which has been carefully designed and well described in 
hundreds of studies. Compared to case-control studies, the prospective cohort design 
holds some advantages. For instance, the participants were unaware of future disease 
when entering the cohort, which minimises the possibility of information bias or that 
the knowledge of disease has affected the lifestyle and habits of the participants 
before baseline information was collected. Furthermore, selection bias is minimal in 
cohort studies and usually caused by differentiated loss of participants during follow-
up between the case group and cohort as a whole. In this regard, the cohort has been 
well accounted for, and loss to follow-up was minimal. Thus, selection bias was 
unlikely to be substantial in the studies.  
It is important to consider the generalisability of the studies. The Diet, Cancer and 
Health study included middle-aged subjects (50-64 years at baseline) without previous 
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history of cancer, and for the present studies we excluded subjects with a previous 
history of MI as well. Of all the subjects that were invited, 35% agreed to participate, 
so it is possible that the study cohort is somewhat different from the general population 
that was invited. Notably, it was found that the participants in the study had a better 
socio-economic status than the invited group all together (110). This is, however, a 
common problem in cohort studies, and it is possible that the group that did not 
participate could have contributed a relatively high or perhaps more likely a relatively 
low intake of fish, which would then have resulted in a wider range of the exposure in 
Study I, II & IV and, in turn, a more pronounced effect of the exposure. It is therefore 
possible that the non-acceptance group, given that they provide more extreme levels 
of the exposure, would augment the associations between the exposure and outcome. 
Given the lower socio-economic status, it is also plausible that the non-acceptance 
group would have a higher morbidity and prevalence of various risk factors for MI. 
However, it is less likely that this would influence the associations between fish intake 
and MI substantially. 
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CHAPTER 7. CONCLUSIONS AND 
PERSPECTIVES 
Overall conclusions 
We examined the association of fish consumption and adipose tissue content of 
marine n-3 PUFA with incident MI, and in general, the results showed a modest 
inverse association between incident MI and consumption of fatty fish as well as the 
content of EPA in adipose tissue. In contrast, no effect was demonstrated from 
consumption of lean fish. Thus this thesis provide further support for the hypothesis 
that consumption of fatty fish and n-3 PUFA is beneficial in primary prevention of MI.  
Next, we examined polymorphisms in the 5-LOX pathway and found some individual 
SNPs to be associated with MI. Furthermore, haplotypes identified in earlier studies 
were not associated with MI in our population. Taken together, our results suggest 
that the 5-LOX pathway may play a role in the risk of MI. However, when comparing 
our findings to those of other studies examining polymorphisms in the 5-LOX pathway, 
no evident patterns was found, and studies on the pathway have failed to identify 
strong genetic determinants and functional polymorphisms in most of the candidate 
genes. 
We then explored potential interaction between substrates for the 5-LOX pathway and 
variants of a tandem repeat polymorphism in the ALOX-5 gene. The results suggested 
a functional relationship between substrate availability and the genotype, collectively 
affecting the risk of MI. However, though our results indicated interaction, the study 
was inconclusive because of lack of power to detect interaction at the level of 
statistical significance. Thus, we cannot completely rule out that our results in Study 
IV were coincidental, but nevertheless, the study illustrates the importance of complex 
environment-gene interactions and that these should be carefully considered. 
Perspectives 
CVD remains a leading cause of death worldwide, despite markedly improved 
treatment of acute coronary syndromes and prevention of CVD, during the last two 
decades. Thus, improvement of both primary and secondary prevention of CVD is of 
major importance. In this regard, marine n-3 PUFA have long been recommended for 
the secondary prevention of CHD. Evidence from cohort studies have generally 
supported the opinion that marine n-3 PUFA may have a role in primary prevention of 
CHD as well, which was supported by the results from this thesis. However, in our 
cohort, the associations were modest compared to early prospective cohort studies. 
Furthermore, recent secondary prevention trials have reported neutral associations 
between fish intake and clinical endpoints, questioning the beneficial effects of n-3 
PUFA, and a gap between the evidence from primary and secondary prevention trials 
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have become more evident. All together, these discrepancies have stimulated a 
renewed interest and discussion on dietary recommendations with regards to marine 
n-3 PUFA, and future studies should aim at clarifying these discrepancies between 
primary and secondary prevention trials. For instance, it would be of interest to look 
into aspects of dietary substitution to help explain differences between dietary fish 
intake and fish oil supplements. Also, the role of n-3 PUFA in the context of aggressive 
medical therapy, which might influence on the mechanisms of action for n-3 PUFA, 
needs further investigation. Finally, differential effects for individual n-3 PUFA have 
been suggested, but trial evidence is limited especially for DPA. 
The 5-LOX pathway is an inflammation related pathway that has been implicated in 
atherothrombotic disease, and genetic association studies have provided some 
support for this relationship. However, important discrepancies exist between studies 
and although some of these discrepancies may be explained by differences in the 
study design and the populations examined, strong genetic determinants remains to 
be confirmed. Importantly, some studies have found evidence of diet-gene interaction 
by substrates for the 5-LOX enzymes, which should be carefully considered in future 
studies examining the pathway. Another aspect that may be important, is the 
possibility that several common polymorphisms may interact downstream the 
enzymatic pathway, to influence the production of leukotrienes all together. This have 
lead some authors to suggested that a "pathway approach" may be more appropriate, 
and a study examining aspects of gene-gene interaction in our data, is currently being 
planned. Despite inconsistencies in genetic association studies, the 5-LOX pathway 
remains an essential inflammatory pathway implicated in several inflammatory 
diseases such as atherosclerosis and bronchial asthma, and future research may 
provide new targets for treatment of theses widespread diseases, via the 5-LOX 
pathway or leukotrienes. 
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CHAPTER 8. ENGLISH SUMMARY 
Cardiovascular disease (CVD) remains a leading cause of death worldwide and 
atherosclerosis has been recognised as an essential component of the disease. The 
mechanisms leading to atherosclerosis has not been fully uncovered, but several 
researchers has suggested that inflammatory processes in the vessel wall plays an 
important role. In this setting, researchers have developed an interest in the 
leukotrienes that have been associated with atherothrombotic disease. The 
leukotrienes are highly pro-inflammatory substances formed by specific n-3 and n-6 
fatty acids, but the leukotrienes formed by n-3 fatty acids are considerably less pro-
inflammatory compared to leukotrienes formed from n-6 fatty acids. The samme fatty 
acids has been implicated in CVD, where n-3 fatty acids from fatty fish has been 
associated with a lower risk of CVD, whereas other studies have suggested that n-6 
fatty acids may be associated with higher risk of CVD. Thus, it is plausible that the 
dietary intake of specific n-3 and -6 fatty acids may influence the risk of atherosclerotic 
disease through their formation of different types of leukotrienes. 
In his PhD-study we investigated the association between marine n-3 fatty acids, 
evaluated from dietary intake of fish and adipose tissue content of marine n-3 fatty 
acids, and myocardial infarction (MI) in two independent studies. Secondly, we 
investigated genetic variants in four genes involved in the formation of leukotrienes, 
and how the genotypes were associated with MI. Finally, we investigated the interplay 
between a specific genetic variant and adipose tissue content of n-3 and n-6 fatty 
acids in relation to MI. The studies were based on a large Danish cohort study, the 
Diet, Cancer and Health Study, that included more than 57.000 participants and 
currently has been followed for more than 17 years. During this period we identified 
and validated 3.089 cases with incident MI. 
In the two studies examining marine n-3 fatty acids, we found a moderate lower risk 
of MI in the groups with a high intake or content of n-3 fatty acids, which is in line with 
the current opinion among many researchers, that consumption of fatty fish and n-3 
fatty acids is beneficial in the prevention of CVD. Furthermore, our study investigating 
genetic variants in the leukotriene pathway found some variants to be associated with 
MI, and collectively, the study suggested that the leukotriene pathway may play a role 
in the risk of MI. Finally, examining the interaction between a specific polymorphism 
in the leukotriene pathway and adipose tissue content of n-3 and -6 fatty acids, the 
study indicated that the effect of the polymorphism was modified by the content of the 
respective fatty acids. Thus, a high content of the n-3 fatty acid attenuated the effect 
of the variant genotype, while a high content of the n-6 fatty acid augmented the effect 
of the variant.   
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CHAPTER 9. DANSK RESUMÉ 
Hjerte-kar-sygdom er fortsat en af de hyppigste dødsårsager på verdensplan og 
åreforkalkning er en central del af sygdomsprocessen. Mekanismerne bag udviklingen 
af åreforkalkning er endnu ikke fuldt klarlagt, men flere forskere har foreslået, at 
inflammatoriske processer i karvæggen spiller en afgørende rolle. I denne forbindelse 
findes en gruppe af stoffer med stærke inflammationsfremmende egenskaber, kaldet 
leukotriener, som er blevet kædet sammen med risiko for hjerte-kar-sygdom. Disse 
dannes ud fra bestemte n-3 og -6 fedtsyrer, men leukotrienerne, der dannes ud fra en 
n-3 fedtsyre, er markant mindre pro-inflammatoriske end dem, der dannes ud fra en 
n-6 fedtsyre. De samme fedtsyrer er også blevet kædet sammen med hjerte-kar-
sygdom, hvor n-3 fedtsyrer, der findes i fede fisk, er blevet fundet at have en 
beskyttende virkning på hjerte-kar-sygdom. Derimod har andre undersøgelser vist, at 
n-6 fedtsyrer kan øge risikoen for hjerte-kar-sygdom. Det er således muligt, at indtaget 
af n-3 og -6 fedtsyrer gennem kosten, kan have betydning for udviklingen af 
åreforkalkning gennem dannelsen af forskellige typer af leukotriener. 
I dette ph.d.-studie undersøgte vi i to studier, hvorledes indtaget af fisk og indholdet 
af n-3 fedtsyrer i fedtvæv var associeret med akut myokardieinfarkt. Dernæst 
undersøgte vi i et tredje studie variationer i generne, der er involveret i dannelsen af 
leukotrienerne, og hvordan genotypen var associeret med akut myokardieinfarkt. Til 
slut undersøgte vi samspillet mellem en udvalgt gen-variant og indholdet af n-3 og -6 
fedtsyrer i fedtvæv i relation til akut myokardieinfarkt. Studierne tog udgangspunkt i 
en stor dansk befolkningsundersøgelse, Kost, kræft og helbred som inkluderede mere 
end 57.000 personer, og som på nuværende tidspunkt er blevet fulgt i mere end 17 
år i gennemsnit. I denne periode identificerede og validerede vi 3.089 personer med 
akut myokardieinfarkt. 
De to første studier fandt en moderat lavere risiko for akut myokardieinfarkt i 
grupperne med højt indtag af fed fisk eller højt indhold af n-3 fedtsyrer i fedtvæv, 
hvilket støtter den generelle opfattelse at indtaget af n-3 fedtsyrer fra fisk har en 
beskyttende virkning mod hjerte-kar-sygdom. Dernæst viste vores undersøgelse af 
genetiske varianter i leukotriensystemet, at nogle af polymorfierne var associeret med 
risikoen for akut myokardieinfarkt og samlet set viste studiet, at leukotriensystemet 
muligvis har en betydning for risikoen for akut myokardieinfarkt. I studie IV, hvor vi 
undersøgte vekselvirkning mellem en genetisk polymorfi i leukotriensystemet og n-3 
og -6 fedtsyrer, indikerede resultaterne at effekten af polymorfien blev modificeret af 
n-3 og -6 fedtsyrerne, således at et højt indhold af n-3 fedtsyren i fedtvæv svækkede 
effekten af varianterne hvorimod et højt indhold af n-6 fedtsyren i fedtvæv øgede 
effekten af varianterne. 
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Abstract
Several studies have investigated the potential benefits of marine n-3 PUFA in CVD, generally suggesting a lower risk of CHD. However,
recent trials have questioned these results. This study investigated the association of fish consumption with dietary intake of marine n-3 PUFA
with incident myocardial infarction (MI). In a Danish cohort study, 57053 subjects between 50 and 64 years of age were enrolled from 1993 to
1997. From national registries, we identified all cases of incident MI. Dietary fish consumption was assessed using a semi-quantitative food
questionnaire, including twenty-six questions regarding fish intake. In addition, we calculated the intake of total and individual marine
n-3 PUFA. During a median follow-up of 17·0 years, we identified 3089 cases of incident MI. For both men and women, a high intake of fatty
fish was inversely related to incident MI. Thus, when comparing the highest and the lowest quintile of fatty fish intake, we found a 12%lower
relative risk of MI in men (hazard ratio (HR) 0·88; 95%CI 0·77, 1·00) and a 22%lower relative risk in women (HR0·78; 95%CI 0·63, 0·96) after
adjustments. For women, similar associations were observed for individual and total marine n-3 PUFA. In contrast, intake of lean fish was not
associated with MI. In conclusion, incident MI was inversely related to a high intake of fatty fish, but not lean fish. However, test for trends
across quintiles was not statistically significant. In general, this study supports the view that consumption of fatty fish may protect against MI.
Key words: Myocardial infarction: Cohort studies: Mar ine n -3 PUFA: Fish consumption
The potential benefit of marine n-3 PUFA on CHD has been
extensively examined in both observational studies and clinical
trials, with the majority of studies favouring a beneficial effect of
n-3 PUFA(1–4).
Thus, several prospective cohort studies have reported an
inverse relationship between fish consumption and CHD(1,5–14).
However, other studies have not supported these findings(15,16).
Most epidemiological studies have evaluated the dietary intake
of fish using questionnaires, but relatively few of these studies
have differentiated between different types of fish and their
content of marine n-3 PUFA. In this study, we evaluated
fish intake using detailed and validated FFQ, allowing us to
differentiate between consumption of fatty and lean fish, and
additionally to calculate the intake of total and individual
marine n-3 PUFA.
Large secondary prevention trials have been performed
evaluating dietary interventions with fish servings or supple-
mentation with fish oil capsules. Although earlier trials such
as the diet and reinfarction trial(17), Gruppo Italiano per lo
Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)
Prevenzione(18) and Japan EPA Lipid Intervention Study trials(19)
have demonstrated a reduction in CHD events following
consumption of marine n-3 PUFA, more recent trials have not
supported these findings(20–22). Controversy therefore still
remains regarding the potential benefits from fish consumption
and n-3 PUFA supplements in the prevention of CHD, and
guidelines are currently under review.
In this large Danish cohort study, including 3089 validated
cases of incident myocardial infarction (MI), we investigated the
association of fish consumption and dietary intake of marine
n-3 PUFA with incident MI. The present study is one of the
largest cohort studies on fish consumption and MI, and notably
the study includes a relatively high number of female cases.
Methods
Study population and design
The Danish Diet, Cancer and Health study is a prospective
cohort study, which has been described in detail previously(23).
Abbreviations: DPA, docosapentaenoic acid; ICD; International Classification of Disease; MI; myocardial infarction.
* Corresponding author: A. Gammelmark , email anders.gammelmark@rn.dk
British Journal of Nutrition (2016), 116, 167–177 doi:10.1017/S000711451600180X
© The Authors 2016
MARINE N-3 FATTY ACIDS AND GENETIC VARIANTS IN THE 5-LIPOXYGENASE PATHWAY 
APP 2 
 
APPENDIX A. PAPER I 
APP 3 
 
MARINE N-3 FATTY ACIDS AND GENETIC VARIANTS IN THE 5-LIPOXYGENASE PATHWAY 
APP 4 
 
APPENDIX A. PAPER I 
APP 5 
 
MARINE N-3 FATTY ACIDS AND GENETIC VARIANTS IN THE 5-LIPOXYGENASE PATHWAY 
APP 6 
 
APPENDIX A. PAPER I 
APP 7 
 
MARINE N-3 FATTY ACIDS AND GENETIC VARIANTS IN THE 5-LIPOXYGENASE PATHWAY 
APP 8 
 
APPENDIX A. PAPER I 
APP 9 
 
MARINE N-3 FATTY ACIDS AND GENETIC VARIANTS IN THE 5-LIPOXYGENASE PATHWAY 
APP 10 
 
APPENDIX A. PAPER I 
APP 11 
 
APPENDIX B. PAPER II 
APP 13 
Appendix B. Paper II 
APPENDIX B. PAPER II 
APP 15 
 
 
 
MARINE N-3 FATTY ACIDS AND GENETIC VARIANTS IN THE 5-LIPOXYGENASE PATHWAY 
APP 16 
 
APPENDIX C. PAPER III 
APP 17 
Appendix C. Paper III 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
MARINE N-3 FATTY ACIDS AND GENETIC VARIANTS IN THE 5-LIPOXYGENASE PATHWAY 
APP 18 
 
  
Title page 
Title: 
Common Polymorphisms in the 5-Lipoxygenase Pathway 
and Risk of Incident Myocardial Infarction: A Danish Case-
Cohort Study 
 
Short title: 
Polymorphisms in the 5-Lipoxygenase Pathway and Risk 
of Myocardial Infarction 
 
Authors:  
Anders Gammelmark
1,2
*, Michael S. Nielsen
1
, Søren Lundbye-Christensen3, Anne Tjønneland4, 
Erik B. Schmidt
1,2
, Kim Overvad
1,5
 
 
Affiliations: 
1
 Department of Cardiology, Aalborg University Hospital, Aalborg, Denmark.
  
2
 Department of Clinical Medicine, Aalborg University, Aalborg, Denmark. 
3
 Unit for Clinical Biostatistics and Bioinformatics, Aalborg University Hospital, Aalborg, 
Denmark. 
4
 Danish Cancer Society Research Center, Copenhagen, Denmark. 
5
 Section for Epidemiology, Department of Public Health, Aarhus University, Aarhus, Denmark. 
 
*Corresponding author:  
E-mail: anders.gammelmark@rn.dk (AG) 
  
APPENDIX C. PAPER III 
APP 19 
 
  
Abstract 
The 5-lipoxygenase pathway (5-LOX) has been implicated in the development of cardiovascular 
disease and studies have suggested that genetic polymorphisms related to key enzymes in this 
pathway may confer risk of myocardial infarction (MI). This study investigated the association of 
pre-selected genetic polymorphisms in four candidate genes of 5-LOX (arachidonate 5-
lipoxygenase and its activating protein (ALOX-5 and FLAP), leukotriene A4 hydroxylase (LTA4-H) 
and leukotriene C4 synthase (LTC4-S)) with incident MI. 
In a Danish cohort including 57,053 participants, aged 50-64 at enrolment and 
recruited from 1993-97, we conducted a case-cohort study including cases with incident MI and a 
randomly selected sub cohort of 3,000 participants. Cases were identified from national registries 
through July 2013. A total of 22 SNPs were selected and genotyped using the commercially 
available KASP™ assay. A tandem-repeat polymorphism, located in the ALOX-5 gene, was 
genotyped by multi-titre plate sequencing. Haplotypes were inferred using PHASE 2.1. 
During a median follow-up of 17.0 years we identified 3,089 cases of incident MI. In 
FLAP, two SNPs were negatively associated with incident MI (rs9551963 & rs17222842) while one 
SNP (rs2247570) located in LTA4-H, was associated with higher risk of MI when comparing 
subjects with two copies of the variant allele to homozygotes for the wild type. Furthermore, the 
promoter polymorphism rs59439148 was associated with risk of MI in men. For male carriers of 
two variant alleles we found a hazard ratio of 1.63 (95% CI: 1.06;2.52) compared to homozygotes 
for the wild type. Previously described haplotypes (Hap-A -B, -E and –K) were not associated with 
MI in our population.  
In conclusion, common polymorphisms in the 5-lipoxygenase pathway were 
associated with incident MI, suggesting a potential role for this pathway in the development of 
cardiovascular disease. 
 
Introduction 
Atherosclerosis is a multifactorial disease involving both environmental and genetic factors. In 
recent years, focus has turned on the complex cascade of inflammatory processes that takes place in 
the vessel wall and within atherosclerotic plaques [1,2]. In this context the 5-lipoxygenase (5-LOX) 
pathway has received attention. Thus, the 5-LOX pathway metabolizes arachidonic acid (AA), 
leading to the formation of highly pro-inflammatory lipid mediators called leukotrienes (LTs) [3]. 
The 5-LOX pathway consists of four key enzymes, where arachidonate 5-lipoxygenase (ALOX-5) 
and the ALOX-5 activating protein (FLAP) constitutes the first enzymatic step followed by 
conversion to either leukotriene C4 synthase (LTC4-S) or leukotriene B4 hydroxylase (LTB4-H) 
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resulting in the formation of either cysteinyl leukotrienes or B-series leukotrienes, respectively (Fig 
1).  
 
Fig 1. Schematic outline of the 5-LOX pathway leading to the formation of leukotrienes 
The figure gives a schematic overview of the formation of 4-series leukotrines from arachidonic 
acid. The first step is catalysed by 5-lipoxygenase and 5-lipoxygenase activating protein (FLAP), 
which is also the rate-limiting step in the pathway. Next, leukotriene A4 is rapidly metabolised to 
either leukotriene B4 or the cysteinyl leukotrienes by leukotriene A4-hydroxylase or leukotriene 
C4-synthase, respectively. 
  
Evidence at multiple levels, including animal, biochemical and human studies, has 
linked this pathway and the bioactive LTs to the development of atherosclerosis and athero-
thrombotic disease [3–7]. Thus, in a mouse model, it was demonstrated that the knock out of the 
ALOX-5 gene led to a high resistance against the development of atherosclerosis [8]. Other aspects 
of the 5-LOX pathway have been implicated in atherosclerosis traits in animal studies, including the 
leukotriene B4 – receptor [9,10] and the FLAP gene [11]. Furthermore, studies on human 
atherosclerotic plaques have identified the presence of 5-LOX enzymes and levels of ALOX-5 were 
higher in the more advanced plaques [12]. In addition, high levels of ALOX-5 and LTA4-H in 
human plaques have been associated with symptoms of plaque instability [13,14], suggesting a key 
role of the 5-LOX pathway in late stages of atherosclerosis and atherothrombotic events. 
A number of epidemiological studies have examined four candidate genes, encoding 
the enzymes involved in the 5-LOX pathway. Most attention has been focused on ALOX-5 and 
FLAP, where Dwyer et al. examined a tandem repeat polymorphism in the promoter region of 
ALOX-5 that was associated with higher intima-media thickness of the carotid arteries, a marker of 
atherosclerosis, when comparing carriers of the variant allele with homozygotes of the wild type 
allele [15]. This polymorphism has been investigated in a number of studies with different 
endpoints, including ischemic stroke and MI [16–20], but the results have been conflicting.  
In a genome-wide association study, the deCODE investigators identified FLAP as an 
important gene involved in atherothrombotic disease and reported two haplotypes (Hap-A and Hap-
B) that were associated with higher risk of MI and stroke [21,22]. Some studies have supported 
these findings [23–27] while others did not find these haplotypes to be associated with risk of MI or 
stroke [19,28–30].  
The deCODE investigators also defined a risk haplotype (Hap-K) for MI [31], 
covering the LTA4-H gene which was confirmed by other investigators [19,32]. Following these 
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studies, Zhao et al. defined a new haplotype (Hap-E) that was associated with a lower risk of MI 
among carriers compared to non-carriers [30]. 
Finally, two promoter polymorphisms have been identified in LTC4-S and 
investigated in three studies, with conflicting results [33–35]. 
 Thus, from previous studies on four candidate genes, encoding key enzymes in the 5-
LOX pathway, it has been suggested that genetic variants may be associated with atherosclerotic 
disease. Following a review of the literature, we selected 22 SNPs from these four candidate genes 
to investigate the association with incident MI in a large Danish cohort study. 
 
Materials and Methods 
Study design and population 
The Danish Diet, Cancer and Health study is a prospective cohort study, which has been described 
in detail previously [36]. Briefly, 160,725 persons aged 50-64 years were invited between 
December 1993 and May 1997. Eligible participants were born in Denmark, living in the urban 
areas of Copenhagen and Aarhus and not registered with a cancer diagnosis in the Danish Cancer 
Registry at the time of invitation. If a cancer diagnosis was found that was not already recorded in 
the Cancer Registry at time of invitation, participants were excluded in line with the intention-to-
include criteria. Further, participants registered with a previous MI or cardiac arrest were excluded 
as well. At baseline, each participant filled in a detailed questionnaire on diet, lifestyle, socio-
economic status and medical history. Blood and adipose tissue samples were collected.  
 For the present study we used a nested case-cohort design including all cases with 
incident MI and a randomly selected sub cohort (n=3,000) to represent the cohort.     
The study was conducted in accordance with the Helsinki Declaration and all participants provided 
written informed consent. The study, including the consent procedure, was approved by The 
Regional Ethics Committee, North Denmark Region (approval number, N-20140071). 
Selection and genotyping of SNPs 
From a review of the current literature, we selected four candidate genes to examine the 5-LOX 
pathway (ALOX-5, FLAP, LTA4-H and LTC4-S). Next, 22 SNP markers were selected based on 
previous reported associations with cardiovascular disease, with preference for coronary artery 
disease, and a confirmed minor allele frequency (MAF) > 0.05 in Caucasians.   
From whole blood, DNA was extracted using Kleargene
TM
 XL DNA extraction kit 
(LGC Genomics, Queens Road, Teddington, Middlesex, UK). Next, contaminants were removed by 
washing and DNA was subsequently eluted into a low salt buffer. Extracted DNA were stored at -
20°C. 
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SNP genotyping was performed by LGC Genomics using the commercially available 
KASP
TM
 genotyping assay. KASP is based on a competitive, allele specific PCR genotyping 
technique with a homogenous fluorescent based reporting system [37]. The reaction mix was 
aliquoted to standard 96-well plates containing DNA-samples from the study cohort, including at 
least one "no template control" per plate. PCR was performed and the fluorescent signal was 
analysed using a BMG PHERAstar plate reader (BMG Labtech Ltd., Aylesbury, UK). The analysis 
was performed according to the protocol provided by LGC Genomics [38]. SNP alleles correspond 
to the positive/forward DNA-strand according to dbSNP, human assembly GRCh38.p2 [39].    
Genotyping of ALOX-5 tandem repeat polymorphism       
The tandem repeat polymorphism was analysed by microtitre plate (MTP)-sequencing technique, 
using standard 96-well plates. PCR-products were prepared from genomic DNA, using MyTaq
TM
 
DNA polymerase (Bioline US Inc.) along with the following primers: 5’-
TCAGGAGAGAACGAGTGAAC-3’ (forward) and 5’-GTCCAGGTGTCCGCATC-3’ (reverse). 
40 reaction cycles were performed at 55°C. From the PCR-products, sequencing was done using an 
ABI 3730XL DNA analyser (Thermo Fischer Scientific Inc.) and Chromatograms were interpreted 
by a trained laboratory technician, identifying the number of tandem-repeats for each allele.  
Outcome assessment  
We identified all participants in the cohort who were registered with an incident diagnosis of MI in 
the Danish National Patient Registry and/or the Danish Causes of Death Registry, according to the 
International Classification of Disease (ICD) 8 (410.00-410.99) or ICD-10 (I21.0-I21.9) coding, 
during the study period. Furthermore, all cases of cardiac arrest (ICD-8: 427.27 or ICD-10: I46.0-
I46.9) were included if the arrest was considered to be of cardiac origin after validation in each 
individual case. An earlier study from our Department validated the MI diagnosis from baseline 
through 2003 by complete review of all medical records and found a positive predictive value above 
92 % when the diagnoses were obtained from a hospital ward [40]. All validated cases of MI from 
this validation study were included as cases for the present study. From January 2004 through July 
2013 all participants with an incident MI diagnosed from a ward were readily accepted as cases 
without further validation. All other diagnoses of incident MI and cardiac arrest were validated by 
reviewing a complete list of diagnoses and interventional procedures recorded in the Danish 
National Patient Registry for each potential case. 
Statistics 
Allele frequencies were tested for Hardy–Weinberg equilibrium (HWE) in the sub cohort using a 
chi-square test (X
2
-test). SNPs deviating from HWE (p < 0.05) were excluded from further analysis. 
We inferred haplotypes for combinations of SNPs using the program PHASE, version 2.1 [41,42]. 
In brief, the PHASE algorithm implements a Bayesian statistical method for reconstructing 
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haplotypes from observed genotype data, dealing with missing data by imputing missing genotypes. 
The program constructs diplotypes for each individual with probability estimates for each diplotype. 
Weights, from the probability estimates derived from PHASE, were implemented in the analyses as 
described by French et al. [43].  
 SNPs were analyzed as categorical variables with two degrees of freedom, assuming a 
general model of inheritance. To correct for multiple comparisons, we estimated the number of 
independent tests within each candidate gene, taking into account the correlation between SNPs by 
estimating the composite linkage disequilibrium (LD) correlation matrix from the SNP data, as 
described by Gao et al. [44]. Next, p-values were adjusted according to the number of independent 
tests derived from the correlation matrix using Sidák corrections [45]. Haplotype analyses were 
performed for previously described haplotypes in a univariate model, comparing the risk haplotype 
against all other haplotypes by including only the risk haplotype in the Cox model. Additionally, we 
evaluated all common haplotypes within FLAP and LTA4-H using a multivariate model. In this 
model, the most common haplotype was selected as reference and all common haplotype 
combinations (frequencies > 1%) derived from PHASE were compared to the common haplotype 
by including all haplotypes as covariates in the Cox model, except for the most common haplotype. 
For both the uni- and multivariate models, each haplotype was evaluated, comparing non-carriers 
with carriers of one or two copies of the haplotype, assuming linearity for the haplotype effect 
[43,46]. 
 Measures of association were assessed using Cox proportional hazards multivariate 
regression models with age as the time axis and delayed entry. In accordance with the case-cohort 
design, we used a weighting scheme and robust variance estimates as described by Kalbfleisch and 
Lawless [47]. For the haplotype analyses, these weights were multiplied with the probability 
weights derived from PHASE. Analyses were conducted for the whole study cohort and separately 
for men and women, but the pooled analysis was considered as the primary. Participants were 
treated as at risk from baseline until either MI, death, emigration or end of follow-up occurred. 
 To address potential confounding we adjusted for traditional risk factors for MI 
(model A2) including smoking habits (never, former or current (<15 g/day, 15-25 g/day, >25 g/day) 
smoker), body mass index (kg/m
2
), waist circumference (cm), physical activity (hours/week), 
alcohol intake (g/day), educational level (basic school, higher education: 1-3 years or >3 years) and, 
for women, menopausal status (pre- or post-menopausal). All continuous variables were included in 
the models as restricted cubic splines with five knots. Potential confounders were selected a priori 
based on current knowledge of risk factors for MI. In light of our primary exposure, being genetic 
polymorphisms, we did not expect confounding to be of major concern. 
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The proportional hazards assumption was checked by visual inspection of log-log 
plots and by evaluation of scaled Schoenfeld residuals with no violations of the assumption. P-
values (two-tailed) < 0.05 were considered statistically significant. STATA, version 14.1 
(StataCorp, College Station, TX, US) was used as statistical software. 
 
Results 
Population characteristics 
From an initial 160,725 invited participants, a total of 57,053 (35%) accepted the invitation, and 
were enrolled into the study. From these, we excluded 1,506 participants due to missing baseline 
questionnaires or if recorded with a cancer diagnosis or having a previous MI or cardiac arrest 
before baseline. In our study population we identified 3,089 cases of incident MI during a median 
follow-up time of 17.0 years. After case verification, we excluded subjects for whom information 
regarding one or more potential confounders was missing. Additionally, 255 subjects were missing 
DNA-samples. In total, 2,876 cases were included in the analyses (Fig 2). For individual SNPs, 
genotype information was missing in 57 to 148 subjects.   
 As expected, traditional risk factors for MI were more prevalent among cases then in 
the sub cohort (Table 1). 
 
Fig 2. Flow chart of cohort selection process 
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Association between ALOX-5 tandem-repeat polymorphism and MI 
A tandem-repeat polymorphism, located close to the promoter region of ALOX-5, was analyzed by 
traditional sequencing (rs59439148). The genotype frequencies, according to the number of 
hexamer-repeats (‘-CCCGCC-’) for the two alleles, are presented in Table 2. The 5-repeats allele 
was by far, the most common allele (84.4%). Next, the 4-repeats was the most frequent variant 
allele observed (15.2%). Alleles with less than 4-repeats were rare (<1%). As a result of the 
observed allele frequencies, we analyzed the tandem repeat defining the 5-repeats allele as the wild 
type and alleles with less than 5-repeats as the variant alleles. Frequencies of the constructed variant 
and wildtype are reported in Table 3. In men, the tandem-repeat polymorphism, rs59439148, was 
positively associated with MI when comparing homozygous carriers of the variant with carriers of 
the wild type (HR=1.63 with 95% CI: 1.06;2.52), suggesting a recessive genetic effect (S1 Table 
4A). However, no association was seen for women and the combined analyses were not statistically 
significant (Table 4), although the hazard ratios suggested a positive association as in men.    
In addition to the tandem-repeat polymorphism we also analyzed the SNP, rs12762303, that was 
previously shown to be in close LD with the variant and wild type allele of the tandem-repeat [29]. 
As anticipated, this SNP was in almost perfect LD with the tandem-repeat polymorphism 
(D’=0.99), and the measures of association were very similar to the tandem-repeat polymorphism. 
 
Table 2. Distribution of genotypes for the ALOX-5 promoter polymorphism, according to 
number of tandem repeats (5'-GGGCGG-3'). 
Genotype Sub cohort Cases 
22 - - - - 
23 - - - - 
24 2 (0.07) 2 (0.07) 
25 17 (0.59) 11 (0.38) 
26 - - - - 
33 - - - - 
34 3 (0.10) 1 (0.03) 
35 1 (0.03) 3 (0.10) 
36 - - - - 
44 73 (2.55) 82 (2.85) 
45 717 (25.09) 679 (23.61) 
46 - - - - 
55 2,004 (70.12) 2,039 (70.90) 
56 - - - - 
66 - - 1 (0.03) 
Abbreviations: ALOX-5, Arachidonate 5-lipoxygenase. 
Reported as number of subjects with frequencies in parentheses (%). No observations are indicated 
with a dash. 
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Table 3. Minor allele frequency for each SNP, selected from four candidate genes in the 5-
LOX pathway. 
SNP Genomic position Allele Sub cohort Cases 
ALOX-5       
rs12762303 10: 45373723 C/T 14.9 (833) 14.4 (809) 
rs59439148 10: 4537413(2-7) V/W 15.8 (891) 15.3 (863) 
FLAP       
rs17222814  13: 30725416 A/G 11.0 (619)  10.6 (599) 
rs4073259 13: 30732134 G/A 35.9 (2,004) 35.3 (1,983) 
rs10507391 13: 30737959 A/T 32.9 (1,855) 32.4 (1,836) 
rs4769874 13: 30752304 A/G 3.8 (213) 3.6 (200) 
rs9551963 13: 30758410 A/C 50.3 (2,831) 48.2 (2,723) 
rs9315050 13: 30761908 G/A 6.1 (342) 6.5 (366) 
rs17222842 13: 30765980 A/G 10.7 (598) 9.7 (547) 
LTC4-S       
rs730012 5: 179793637 C/A 30.4 (1,705) 31.3 (1,765) 
LTA4-H       
rs61937881 12: 95999809 T/C 24.3 (1,349) 25.7 (1,440) 
rs2660880 12: 96007474 A/G 6.8 (385) 6.8 (387) 
rs6538697 12: 96009832 C/T 7.2 (408) 7.4 (419) 
rs1978331 12: 96015423 C/T 38.3 (2,144) 39.9 (2,249) 
rs17677715 12: 96020673 C/T 17.7 (998) 19.0 (1,076) 
rs2247570 12: 96028599 G/A 29.5 (1,653) 30.8 (1,735) 
rs2660898 12: 96032219 G/T 31.8 (1,783) 33.1 (1,872) 
rs2540482 12: 96041102 G/A 22.5 (1,263) 22.1 (1,251) 
rs2540477 12: 96043776 C/T 22.0 (1,238) 21.7 (1,228) 
rs2660845 12: 96044775 G/A 26.0 (1,460) 25.6 (1,447) 
rs2540475 12: 96047515 T/C 20.5 (1,159) 20.0 (1,131) 
Abbreviations: SNP, Single nucleotide polymorphism; ALOX-5, Arachidonate 5-lipoxygenase; 
FLAP, 5-lipoxygenase activating protein; LTC4-S, Leukotriene C4 synthase; LTA4-H, Leukotriene 
A4 hydroxylase. 
Results presented as allele frequencies (n) for the minor allele(underlined). The two SNPs 
(rs17216473 & rs3776944) did not display variation in our study population. Alleles correspond to 
the positive DNA-strand and genomic position are obtained from dbSNP, human assembly 
GRCh38.p2. 
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Table 4. Association of selected single nucleotide polymorphisms with incident myocardial 
infarction. 
SNP Genotype Model A1* p
a 
p
b 
Model A2** p
a 
p
b 
ALOX-5          
rs12762303 T/T 1 (ref)    1 (ref)    
 C/T 0.94 (0.83;1.07) 0.34 - 0.96 (0.84;1.10) 0.55 - 
 C/C 1.27 (0.87;1.86) 0.22 - 1.37 (0.91;2.05) 0.13 - 
rs59439148 W/W 1 (ref)    1 (ref)    
 W/V 0.94 (0.83;1.06) 0.31 - 0.96 (0.84;1.10) 0.52 - 
 V/V 1.23 (0.89;1.71) 0.21 - 1.35 (0.96;1.90) 0.09 - 
FLAP          
rs17222814  G/G 1 (ref)    1 (ref)    
 G/A 0.91 (0.79;1.05) 0.20 0.74 0.93 (0.80;1.08) 0.34 0.92 
 A/A 1.22 (0.72;2.05) 0.47 0.98 1.18 (0.66;2.10) 0.58 0.99 
rs4073259 A/A 1 (ref)    1 (ref)    
 A/G 0.95 (0.84;1.07) 0.38 0.94 0.93 (0.82;1.06) 0.28 0.86 
 G/G 0.96 (0.81;1.15) 0.69 1.00 0.96 (0.80;1.17) 0.70 1.00 
rs10507391 T/T 1 (ref)    1 (ref)    
 T/A 1.00 (0.89;1.12) 0.99 1.00 0.99 (0.87;1.12) 0.83 1.00 
 A/A 0.94 (0.78;1.14) 0.55 0.99 0.98 (0.80;1.19) 0.82 1.00 
rs4769874 G/G 1 (ref)    1 (ref)    
 G/A 0.96 (0.77;1.19) 0.72 1.00 1.04 (0.83;1.31) 0.74 1.00 
 A/A 0.27 (0.06;1.28) 0.10 0.47 0.33 (0.07;1.61) 0.17 0.67 
rs9551963 C/C 1 (ref)    1 (ref)    
 C/A 0.86 (0.75;0.98) 0.03 0.14 0.83 (0.72;0.96) 0.01 0.07 
 A/A 0.85 (0.73;0.99) 0.04 0.21 0.80 (0.68;0.95) 0.01 0.05 
rs9315050 A/A 1 (ref)    1 (ref)    
 A/G 1.03 (0.87;1.23) 0.71 1.00 1.07 (0.89;1.28) 0.50 0.98 
 G/G 0.66 (0.28;1.55) 0.34 0.92 0.81 (0.34;1.93) 0.63 1.00 
rs17222842 G/G 1 (ref)    1 (ref)    
 G/A 0.97 (0.85;1.12) 0.73 1.00 0.94 (0.81;1.10) 0.45 0.97 
 A/A 0.40 (0.22;0.73) 0.01 0.02 0.44 (0.24;0.82) 0.01 0.05 
LTC4-S          
rs730012 A/A 1 (ref)    1 (ref)    
 A/C 1.11 (0.99;1.25) 0.07 - 1.08 (0.95;1.22) 0.24 - 
 C/C 1.02 (0.83;1.24) 0.88 - 1.00 (0.81;1.24) 0.99 - 
LTA4-H          
rs61937881 C/C 1 (ref)    1 (ref)    
 C/T 1.05 (0.94;1.18) 0.40 0.95 1.02 (0.90;1.16) 0.71 1.00 
 T/T 1.19 (0.94;1.50) 0.14 0.60 1.23 (0.96;1.58) 0.10 0.48 
rs2660880 G/G 1 (ref)    1 (ref)    
 G/A 1.07 (0.91;1.27) 0.41 0.96 1.06 (0.89;1.28) 0.51 0.99 
 A/A 0.83 (0.41;1.70) 0.61 1.00 0.80 (0.38;1.66) 0.54 0.99 
rs6538697 T/T 1 (ref)    1 (ref)    
 T/C 1.01 (0.86;1.19) 0.88 1.00 1.04 (0.87;1.23) 0.69 1.00 
 C/C 0.99 (0.45;2.21) 0.99 1.00 1.08 (0.48;2.43) 0.85 1.00 
rs1978331 T/T 1 (ref)    1 (ref)    
 T/C 1.06 (0.94;1.19) 0.38 0.94 1.06 (0.93;1.21) 0.38 0.94 
 C/C 1.15 (0.97;1.36) 0.10 0.48 1.19 (0.99;1.43) 0.06 0.30 
rs17677715 T/T 1 (ref)    1 (ref)    
 T/C 1.05 (0.93;1.18) 0.43 0.97 1.04 (0.91;1.18) 0.56 0.99 
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 C/C 1.25 (0.91;1.72) 0.17 0.66 1.29 (0.92;1.81) 0.14 0.59 
rs2247570 A/A 1 (ref)    1 (ref)    
 A/G 1.00 (0.90;1.13) 0.94 1.00 1.00 (0.88;1.13) 0.97 1.00 
 G/G 1.23 (1.01;1.51) 0.04 0.22 1.28 (1.03;1.59) 0.03 0.15 
rs2660898 T/T 1 (ref)    1 (ref)    
 T/G 1.09 (0.97;1.22) 0.17 0.66 1.07 (0.94;1.21) 0.32 0.90 
 G/G 1.09 (0.90;1.32) 0.37 0.94 1.12 (0.92;1.38) 0.26 0.84 
rs2540482 A/A 1 (ref)    1 (ref)    
 A/G 0.95 (0.85;1.07) 0.38 0.94 0.95 (0.84;1.08) 0.44 0.97 
 G/G 1.05 (0.81;1.36) 0.74 1.00 0.98 (0.74;1.30) 0.89 1.00 
rs2540477 T/T 1 (ref)    1 (ref)    
 T/C 0.95 (0.85;1.07) 0.39 0.95 0.95 (0.84;1.08) 0.45 0.97 
 C/C 1.08 (0.83;1.41) 0.58 0.99 1.03 (0.77;1.37) 0.85 1.00 
rs2660845 A/A 1 (ref)    1 (ref)    
 A/G 0.93 (0.83;1.05) 0.25 0.82 0.92 (0.82;1.04) 0.20 0.74 
 G/G 1.04 (0.83;1.31) 0.74 1.00 1.04 (0.81;1.33) 0.76 1.00 
rs2540475 C/C 1 (ref)    1 (ref)    
 C/T 1.00 (0.89;1.12) 0.97 1.00 0.98 (0.86;1.11) 0.72 1.00 
 T/T 0.88 (0.67;1.17) 0.39 0.95 0.90 (0.67;1.21) 0.49 0.98 
Abbreviations: SNP, Single nucleotide polymorphism; ALOX-5, Arachidonate 5-lipoxygenase; 
ALOX-5 AP, Arachidonate 5-lipoxygenase activating protein; LTC4-S, Leukotriene C4 synthase; 
LTA4-H, Leukotriene A4 hydroxylase; LD, linkage disequilibrium. 
The table displays hazard ratios from a weighted cox proportional hazards model. Alleles 
correspond to the positive DNA-strand according to dbSNP, human assembly GRCh38.p2. 
*Crude analyses. The pooled estimates are adjusted for sex. 
**Adjusted analyses including sex(pooled analyses), smoking status, educational level, physical 
activity, BMI, waist circumference and alcohol consumption. 
a
Crude
 
p-value. 
b
Adjusted p-value corrected for multiple testing within each candidate gene. From the composite 
LD correlation matrix the number of independent tests (N) were estimated. Using Sidák corrections, 
we then calculated the adjusted p-value as: p
b 
= 1-(1-p
a
)
N
. 
 
Association of individual SNPs with MI 
We genotyped 22 SNPs and examined associations with incident MI for each SNP individually. 
However, for two SNPs (rs17216473 and rs3776944), our assays were not able to detect the variant 
allele after testing two different assays on the forward strand and afterwards two assays on the 
reverse strand for each of the SNPs. The remaining 20 SNPs all displayed a MAF > 0.05 (Table 3) 
and the allele frequencies were similar to observations in other populations of European origin, 
according to dbSNP [39]. No SNPs deviated from the Hardy Weinberg equilibrium, when tested in 
the sub cohort.  
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 In Table 4 we report hazard ratios for associations between individual SNPs and MI 
for the study cohort. Results are presented for both heterozygous and homozygous carriers of the 
variant allele compared to homozygous carriers of the wild type, assuming a general model of 
inheritance. Sex specific analysis are presented in the supplementary material (S1 Table 4A).    
For FLAP, the SNP rs9551963 was negatively associated with MI when comparing 
both heterozygous and homozygous carriers of the minor allele (A) with homozygous carriers of the 
major allele (C), suggesting a dominant genetic effect. Results were similar across sex, but only 
significant in men. For the combined analyses, we found a HR of 0.80 (95% CI: 0.68;0.95) for 
homozygous carriers of the minor allele. Rs17222842 was also negatively associated with MI, when 
comparing homozygous carriers of the minor allele with homozygotes of the major (HR=0.28 (95% 
CI:0.12;0.63)) in men, while no association was observed in women. 
 Ten SNPs were successfully genotyped in LTA4-H. Rs2247570 was positively 
associated with MI in the combined analyses when comparing homozygous carriers of the minor 
(G) and major allele (A), HR=1.28 (95% CI: 1.03;1.59). This relationship was consistent in both 
men and women, but associations were not statistically significant in the sex-stratified analyses. For 
rs61937881, rs1978331 and rs17677715 we found a positive association between carriers of the 
minor allele and MI compared with carriers of the major allele in women. However, the 
associations were not consistent among men, and the associations were not significant in the 
combined analysis for men and women. 
 Finally, the SNP rs730012, located in proximity to the promoter region of LTC4-S was 
not associated with MI in our data. 
Association of haplotypes with MI  
Results from haplotype analyses are presented in Table 5 and 6. First, we tested single haplotypes, 
previously identified in other studies, using all remaining haplotypes as reference (Table 5). In the 
univariate analysis we did not find any of the previously described haplotypes to be associated with 
MI. Next, we performed multivariate analyses including all common haplotypes (haplotype 
frequency > 0.01) in the Cox-model, except for the most common haplotype, that served as 
reference (Table 6). When comparing carriers of each variant haplotype with carriers of the most 
common haplotype in FLAP, one haplotype was negatively associated with MI (GAGAAA). 
However, the association was modest. For LTA4-H the haplotype, CGTTTATAAT, was negatively 
associated with incident MI.        
LD maps produced from the Haploview software showed that most, but not all the 
selected SNPs within FLAP and LTA4-H, were in high LD with one another. This raises the 
possibility that some degree of recombination within the haplotype blocks had occurred in our 
population (S2 Fig 3).   
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Table 5. Association of selected haplotypes in FLAP and LTA4-H with incident myocardial 
infarction.   
Haplotype Freq. (%) Model A1* p
a 
Model A2** p
a 
FLAP        
Hap-A (GGAT) 14.0 0.97 (0.87;1.08) 0.58 0.92 (0.82;1.04) 0.18 
Hap-B (AAG) 19.8 1.02 (0.93;1.12) 0.71 1.02 (0.92;1.13) 0.71 
LTA4-H        
Hap-K (CGTTTATGGC) 14.5 0.94 (0.85;1.05) 0.28 0.91 (0.82;1.02) 0.12 
Hap-E (CCTGAA) 7.6 1.05 (0.91;1.21) 0.49 1.08 (0.93;1.26) 0.33 
Abbreviations: FLAP, 5-lipoxygenase activating protein; LTA4-H, Leukotriene A4 hydroxylase. 
The table displays hazard ratios from a weighted cox proportional hazards model. Haplotypes were 
defined as follows: Hap-A (rs17222814(G), rs4769874(G), rs9551963(A), rs10507391(T)), Hap-B 
(rs10507391(A), rs9315050(A), rs17222842(G)), Hap-K (rs61937881(C), rs2660880(G), 
rs6538697(T), rs1978331(T), rs17677715(T), rs2247570(A), rs2660898(T), rs2540482(G), 
rs2660845(G), rs2540475(C)), Hap-E (rs61937881(C), rs1978331(C), rs17677715(T), 
rs2660898(G), rs2540482(A), rs2660845(A)). Alleles correspond to the positive DNA-strand 
according to dbSNP, human assembly GRCh38.p2. 
*Crude analyses. The pooled estimates are adjusted for sex. 
**Adjusted analyses including sex(pooled analyses), smoking status, educational level, physical 
activity, BMI, waist circumference and alcohol consumption. 
a
Unadjusted p-value.  
 
Table 6. Multivariate test of haplotypes in FLAP and LTA4-H and association with incident 
myocardial infarction.    
Haplotype Freq. (%) Model A1* p
a 
Model A2** p
a 
FLAP        
GTGCAG 40.6 1 (ref)   1 (ref)   
GAGAAG 16.1 0.95 (0.85;1.06) 0.35 0.94 (0.83;1.06) 0.29 
GAGAAA 8.4 0.89 (0.77;1.02) 0.09 0.86 (0.74;0.99) 0.04 
GAGCAG 3.7 1.19 (0.99;1.44) 0.07 1.18 (0.96;1.44) 0.12 
GAACGG 3.5 0.88 (0.72;1.08) 0.23 0.96 (0.77;1.19) 0.71 
GTGAAG 12.4 0.96 (0.85;1.08) 0.50 0.90 (0.79;1.02) 0.11 
GTGAAA 1.7 0.82 (0.62;1.08) 0.17 0.85 (0.64;1.13) 0.26 
GTGCGG 1.7 0.97 (0.73;1.29) 0.83 0.92 (0.67;1.26) 0.59 
ATGAAG 10.6 0.92 (0.80;1.05) 0.21 0.92 (0.80;1.06) 0.27 
LTA4-H        
CGTTTATAAC 43.7 1 (ref)   1 (ref)   
CGTTTATGGC 14.5 0.96 (0.86;1.07) 0.46 0.93 (0.82;1.05) 0.25 
CGTTTATAAT 2.0 0.74 (0.57;0.96) 0.03 0.75 (0.56;0.99) 0.04 
CGTCTGTAGC 3.1 1.03 (0.82;1.29) 0.81 1.03 (0.81;1.32) 0.80 
CGTCTGTAAC 1.7 0.94 (0.70;1.26) 0.68 1.03 (0.76;1.40) 0.84 
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CGCCTAGAAC 5.5 1.04 (0.88;1.24) 0.63 1.04 (0.87;1.25) 0.65 
CGCCTAGAAT 1.4 0.96 (0.70;1.31) 0.80 1.01 (0.73;1.39) 0.97 
TGTCCGGGGC 6.2 1.12 (0.95;1.32) 0.19 1.16 (0.97;1.38) 0.10 
TGTCCGGAAC 1.7 1.12 (0.86;1.47) 0.40 1.10 (0.83;1.45) 0.51 
TGTCCGGAAT 9.7 1.05 (0.92;1.20) 0.49 1.03 (0.89;1.19) 0.69 
TATCTGGAAT 5.5 1.00 (0.84;1.18) 1.00 1.00 (0.83;1.20) 0.99 
Abbreviations: FLAP, 5-lipoxygenase activating protein; LTA4-H, Leukotriene A4 hydroxylase. 
The table displays hazard ratios from a weighted cox proportional hazards model. All haplotypes 
with a frequency > 0.01 were included in the model except for the most common haplotype that 
represented the reference. Haplotypes were constructed from the following SNPs in order: 
rs17222814, rs10507391, rs4769874, rs9551963, rs9315050, rs17222842 (FLAP) and rs61937881, 
rs2660880, rs6538697, rs1978331, rs17677715, rs2247570, rs2660898, rs2540482, rs2660845, 
rs2540475 (LTA4-H). Alleles correspond to the positive DNA-strand according to dbSNP, human 
assembly GRCh38.p2. 
*Crude analyses. The pooled estimates are adjusted for sex. 
**Adjusted analyses including sex(pooled analyses), smoking status, educational level, physical 
activity, BMI, waist circumferrence and alcohol consumption. 
a
Unadjusted p-value.  
 
Discussion 
In the large Danish Diet, Cancer and Health cohort we undertook a case-cohort study, investigating 
the association between 20 pre-selected SNPs and incident MI. Single SNP analyses identified two 
markers in FLAP that were negatively associated with MI (rs9551963 and rs17222842), and for 
LTA4-H, rs2247570 was positively associated with MI. The tandem repeat polymorphism in ALOX-
5, rs59439148, was positively associated with MI for men, while no association could be 
demonstrated in women. Furthermore, rs12762303 was in almost perfect LD with rs59439148. 
Finally, we performed haplotype analyses, first testing the association between previously reported 
haplotypes and MI with no significant associations found. Next, we tested haplotypes from FLAP 
and LTA4-H in multivariate analyses, including all inferred haplotypes with a frequency > 0.01, 
identifying one haplotype in each gene that was associated with MI. 
 In general, the associations of both single SNPs and haplotypes with MI were modest, 
and for some markers the results differed between men and women. A frequent concern in genetic 
association studies is the problem of multiple comparisons which raises the possibility of false 
positive discoveries (type I errors). We addressed this issue by limiting the number of SNP markers. 
Secondly, the number of statistical tests were minimized, e.g. for the single SNP analysis we tested 
the association with MI, assuming a general model of inheritance and refrained from testing several 
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specific models (e.g. dominant and recessive models). Some genetic association studies also adjust 
the significance threshold for multiple comparisons. A frequently used method is the Bonferroni 
correction which adjusts the significance level by the number of individual tests for each 
hypothesis. However, some authors have criticized this method for being too conservative, and 
thereby introducing false negative discoveries (type II errors) [48]. This is particularly of concern 
when testing multiple SNP-markers that are tightly correlated, and therefore not independent [44]. 
Accordingly, we used the method described by Gao et al. [44] to correct for multiple comparisons, 
taking into account the possible correlation between SNP-markers. We chose to report both the 
adjusted and the unadjusted p-values in Table 4. While, in our opinion, the unadjusted p-values 
represents the most clear interpretation of the data, they might be over optimistic and the results 
should be interpreted cautiously along with the following limitations and strengths to the study 
design. Further, all analyses were hypothesis driven and correction for multiple testing might not be 
of concern in this study. 
Strengths and limitations 
This study was based on a large prospective cohort study, and holds the advantages of the 
prospective design. There was a limited loss to follow-up and the assessment of outcome data was 
thorough and complete. The ethnicity of the study population was homogenous and all participants 
were of Caucasian ancestry. Furthermore, information on several dietary factors, lifestyle and other 
risk factors for MI was collected from the participants at baseline, allowing us to adjust for potential 
confounding. A priori, we did not expect confounding to be a major issue in this study, since the 
inherited genotype is subject to the principles of Mendelian randomization. However, some 
evidence suggests that epigenetics, including environmental factors, may influence on the 
expression of genes. We present the results for the crude model and an adjusted model (A2) 
including the most important risk factors for MI to address potential confounding. Furthermore, 
gender was not expected to biologically modify the associations between genotype and MI 
substantially, thus we considered the pooled analyses including both men and women to be the 
primary analyses. Secondary analyses, for men and women separately, were included as 
supplementary tables. 
 This study also had limitations. The selection of SNPs to cover the variation in each 
candidate gene was mostly based on findings by other studies and the results from genome wide 
scans, using a large number of genetic markers. While this method has proven to be highly effective 
in limiting the number of SNPs required for genotyping and the number of statistical tests to be 
performed, this method did not cover all common genetic variation within the candidate genes. 
Therefore, we cannot completely rule out that our study failed to capture all genetic variants that 
may be associated with our outcome. Two SNPs that were pre-selected could not be successfully 
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genotyped, and despite our efforts, four different assays were not able to detect the minor allele for 
these two SNPs (rs17216473 and rs3776944).  
Even though age was evenly distributed among men and women there were few female cases, 
which made the confidence intervals wider for measures of association when analysing data in 
women, and in particular for rare polymorphisms. The median follow-up was 17.0 years, and 
dietary measures were not assessed during the study period. A long follow-up period allowed us to 
accumulate more outcome events, but subjects might change their lifestyle and habits over time. 
Furthermore, changes in standard medical care and public awareness of disease prevention might 
influence the participants’ risk profile and limit our ability to address confounding. It is however 
unlikely that these changes affect measures of association for genotypes and confounding was a 
minor concern in this study. 
General discussion 
Since the initial findings by Dwyer et al. [15] concerning ALOX-5, and later the deCODE group 
identifying FLAP [21] and LTA4-H [31] as important genes in the 5-LOX pathway, a number of 
studies have been undertaken in effort to replicate and add evidence to these studies. The ALOX-5 
tandem repeat polymorphism (rs59439148) was first found to be associated with higher intima-
media thickness by Dwyer et al. but replications on cases with MI and coronary artery disease 
verified by angiography, more clinically relevant endpoints, have yielded conflicting results. 
Notably, two independent case-control studies on MI patients with Northern European origin 
(Caucasians) did not support an association between variant alleles and MI for this polymorphism 
[17,18]. Another study in a mixed population of Caucasians and African-Americans demonstrated a 
positive association, only in African-Americans [19]. Generally, studies were small and no studies 
reported data on men and women separately. In the present study, we found a positive association 
between carriers of two variant alleles and MI, but interestingly, the association was only present 
among men while there was no association among women. The pooled analysis showed the same 
association as for men, but the test was not statistically significant. While we have no apparent 
biological explanation for the differences between men and women, these inconsistencies may 
either be explained by random variations in the small case-group (women) or by modification of the 
associations by gender. To our knowledge, no previous study has presented data for men and 
women separately and we have no data to compare to our own findings. Other SNPs have been 
explored in ALOX-5 [19,29] but only rs59439148 and SNPs linked to this polymorphism has been 
associated with atherosclerosis traits. We confirmed the findings by Assimes et al. [29], that 
rs12762303 was in near perfect LD with rs59439148 and measures of association were similar for 
these two polymorphisms.    
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 Looking at FLAP, Helgadottir et al. [21] identified two haplotypes, Hap-A and Hap-B, 
that was associated with risk of MI in carriers of Hap-A compared to non-carriers in an Icelandic 
population, while the same was true for Hap-B in a British population. The results were later 
replicated in a Scottish cohort confirming a positive association for Hap-A, but not Hap-B, with 
ischemic stroke [22]. In the present study, we could not confirm the association with MI for Hap-A 
or -B. However, we found two individual SNPs within Hap-A and -B to be associated with MI 
when comparing homozygous carriers of the minor allele vs. the major allele (rs9551963 and 
rs17222842). Other studies have found an association between individual SNPs and MI in these 
haplotype blocks, but no consensus in favor of a certain SNP has been agreed upon.   
 Finally, we analyzed ten SNPs covering a haplotype block in LTA4-H. Again, as for 
FLAP we found some of the individual SNPs to be associated with incident MI but when analyzing 
the previously reported haplotype (Hap-K) we did not find any association with MI in our 
population. 
 Additionally, we performed a global haplotype analyses for FLAP and LTA4-H SNPs, 
in order to explore new and unique haplotype combinations in our cohort. In these analyses we 
included all common haplotypes inferred to our cohort in a multivariate model using the most 
common haplotype as the reference haplotype. By this method we found sporadic associations 
between haplotypes and MI but the associations were modest. This method of analyzing haplotypes 
in a multivariate model is well established, but never the less, it has not been explored in previous 
studies on 5-LOX genes. 
 In the following decade since the deCODE studies, a number of large genome wide 
association studies (GWAS) exploring the role of common SNPs in MI has been conducted [49,50]. 
Notably, none of these studies have highlighted SNPs in the 5-LOX genes investigated in this study 
as important risk variants in MI. However, while these large scale studies have the advantage of 
covering the whole genome, they are not ideal in more specific hypothesis testing involving specific 
pathway genes. In this context, the 5-LOX pathway have been linked to atherosclerosis and MI in a 
variety of studies. The key mechanism linking the 5-LOX pathway to atherosclerosis lies in the 
formation of LT’s and their bioactive properties. Notably, the expression of multiple 5-LOX 
enzymes has been linked to human atherosclerotic plaques and plaque development [12,13]. 
Furthermore, LT’s are known to exert several pro-inflammatory effects including increased 
vascular permeability and chemo-attraction of monocytes [3,4]. Genetic association studies, mainly 
candidate gene studies, have also provided some evidence of a link between the 5-LOX pathway 
and atherosclerotic disease, which is supported by the present study. However, despite a number of 
studies performed it has not been possible to identify and confirm a functional polymorphism in 
most of the candidate genes, except for the tandem repeat polymorphism in ALOX-5 (rs59439148), 
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and the studies performed have been heterogeneous regarding design and results. These 
inconsistencies have led some authors to propose a “pathway approach”, taking into account that 
each step of the 5-LOX pathway may have a small influence on the outcome that can be detected 
when all steps are considered together. Crosslin et al. [32] examined how the expression of 5-LOX 
genes depended on the genotype of rs10507391, while another study found significant gene-gene 
interaction between a selected SNP from each of three 5-LOX genes [35]. Other studies have 
investigated the possibility that substrates of the 5-LOX pathway might interact with genetic 
variants in a complex environment where the effect of the genetic variant is dependent on substrate 
availability [16,51]. 
Conclusion 
In this study we found single SNPs in three out of four candidate genes to be associated with 
incident MI, collectively suggesting that the 5-LOX pathway may play a role in MI. However, the 
associations were modest and some associations were not consistent for men and women separately. 
Association between MI and previously reported haplotypes, Hap-A, -B, -E and -K could not be 
confirmed. 
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2. Abstract 
Background 
Arachidonate 5-lipoxygenase (ALOX-5) is the rate limiting enzyme in the 5-lipoxygenase pathway 
that has been linked to atherothrombotic disease. A functional tandem repeat polymorphism in the 
ALOX-5 gene has been associated with risk of myocardial infarction (MI). However, results from 
previous studies have been inconsistent, and interestingly, two studies reported an interaction 
between dietary intake of ALOX-5 substrates, arachidonic acid (AA) and eicosapentaenoic acid 
(EPA), and genotype.   
Objective 
We investigated the possible interaction between the ALOX-5 tandem repeat polymorphism 
(rs59439148) and adipose tissue content of AA and EPA with incident MI. 
Methods 
In the Danish Diet, Cancer and Health study, we conducted a case-cohort study including 3,089 
cases with incident MI identified from national registries and a randomly selected sub-cohort of 
3,000 participants. Adipose tissue and blood samples were collected at baseline along with 
comprehensive questionnaires on lifestyle and demographic data. The ALOX-5 tandem repeat 
polymorphism was genotyped by multi-titre plate sequencing.  
Results 
Cross tabulation of genotype by quintiles of EPA or AA content indicated a higher risk of MI for 
carriers of two variant alleles. Concerning AA, we observed the highest risk of MI for homozygous 
carriers of the variant in the highest quintile of AA content compared with the reference group with 
a low content of AA and carrying the wild type allele (HR=3.02, 95% CI: 1.41;6;44). In contrast, 
homozygotes for the variant had the highest risk of MI when comparing the lowest quintile of EPA 
content with the reference (HR=2.15, 95% CI: 0.91;5.09). Although our results suggested 
interaction, measures of association were not statistically significant.  
Conclusions 
In this large Danish cohort, homozygous carriers of the variant genotype had a higher risk of MI, 
and results indicated that the association was modulated by adipose tissue content of AA and EPA.  
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3. Introduction 
Atherosclerosis is considered a multifactorial disorder involving complex inflammatory processes 
in the vessel wall [1,2]. In this context, the 5-lipoxygenase pathway (5-LOX) has received attention, 
and has been linked to atherothrombotic disease on multiple levels including both animal and 
human studies [3,4]. 5-LOX enzymes metabolise arachidonic acid (AA) and, to a lesser extent, 
eicosapentaenoic acid (EPA) leading to the formation of pro-inflammatory leukotrienes (LTs) 
(Figure 1). Importantly, the 5-series LTs derived from EPA are much less pro-inflammatory 
compared with 4-series LTs derived from AA [5], and studies have shown that consumption of 
marine n-3 polyunsaturated fatty acids (PUFA) (including EPA) can increase production of 5-series 
LTs at the expense of the more pro-inflammatory 4-series LTs [6]. Replacing AA with EPA may 
therefore elicit a relative anti-inflammatory effect.   
 In line with this, epidemiological studies have generally supported an inverse 
association between fish intake, including EPA, and risk of myocardial infarction (MI) [7,8]. In 
contrast, some studies have reported the intake of AA to be positively associated with the risk of MI 
[9]. We recently tested these findings in a Danish cohort study, the Diet, Cancer and Health study, 
confirming an inverse association of both dietary fatty fish [10] and adipose tissue content of EPA 
[11] with the risk of MI, while AA content in adipose tissue was positively associated with MI [12]. 
As a new approach, we used adipose tissue content of the respective fatty acids which is considered 
a good long-term marker of dietary intake of these fatty acids, and importantly, represents the 
endogenous exposure to these fatty acids [13,14]. 
 A number of studies have examined genetic polymorphisms related to key enzymes in 
the 5-LOX pathway. Most attention has been focused on the rate-limiting step, catalysed by  
arachidonate 5-lipoxygenase (ALOX-5), where Dwyer et al. examined a tandem repeat 
polymorphism in the promoter region of ALOX-5 (rs59439148), containing a varying number of 
SP1 transcription factor binding motifs (5’-GGGCGG-3’). The study found variant alleles 
associated with higher intima-media thickness of the carotid arteries compared with carriers of two 
wild type alleles [15]. Following the initial study, this polymorphism has been investigated in a 
number of studies with different endpoints, including ischemic stroke and MI [16–20], but results 
have been conflicting. Interestingly, some studies have suggested an interaction between genotype 
and intake of marine n-3 PUFA and/or AA [15,16], the substrates of the 5-LOX pathway. Thus, a 
high intake of marine n-3 PUFA seemed to blunt the effect of the variant genotype, while in 
contrast, a high intake of AA tended to exacerbate the effect of the variant genotype. Other studies 
have examined polymorphisms in the ALOX-5 gene, but no polymorphisms, other than the tandem 
repeat has been confidently associated with CVD endpoints. Interestingly the SNP, rs12762303, 
was reported to be in close linkage disequilibrium (LD) with the variant and wild type alleles of the 
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tandem repeat [30], which could provide an easy and more cost-effective means of analysing the 
tandem repeat polymorphism. 
 Taken together, evidence suggests a complex interplay between polymorphisms in the 
5-LOX system and dietary intake of AA and EPA. In this study, we examined the association of this 
ALOX-5 tandem repeat polymorphism with incident MI, taking into account the AA and EPA levels 
in adipose tissue to investigate possible diet-gene interaction. Furthermore, we genotyped the SNP, 
rs12762303, that may prove to be in high linkage disequilibrium (LD) with the tandem repeat.  
 
4. Methods 
Study design and population 
The Danish Diet, Cancer and Health study is a prospective cohort study, which has been described 
in detail previously [21]. Briefly, 160,725 persons aged 50-64 years were invited between 
December 1993 and May 1997. Eligible participants were born in Denmark, living in the urban 
areas of Copenhagen and Aarhus and not registered with a cancer diagnosis in the Danish Cancer 
Registry at the time of invitation. A total of 57,053 persons accepted the invitation and were 
enrolled into the study. Participants registered with a previous MI or cardiac arrest were excluded. 
If a cancer diagnosis was reported that was not already recorded in the Cancer Registry at the time 
of invitation, participants were excluded in line with the intention-to-include criteria. At baseline, 
each participant filled in a detailed questionnaire on diet, lifestyle, socio-economic status and 
medical history. Blood and adipose tissue samples were collected.  
 For the present study we used a nested case-cohort design including all cases with 
incident MI and a randomly selected sub-cohort (n=3,000) to represent the cohort.     
The study was conducted in accordance with the Helsinki Declaration and approved by the regional 
ethics committees. 
 
DNA extraction 
DNA was extracted from whole blood using Kleargene
TM
 XL DNA extraction kit (LGC Genomics, 
Queens Road, Teddington, Middlesex, UK). The Kleargene method employs a detergent-driven cell 
lysis technique, followed by guanidinium isothiocyanate-mediated DNA binding to silica. Next, 
contaminants were removed by washing and DNA was subsequently eluted into a low salt buffer. 
The final DNA product was stored at -20°C until analysis. 
 
Genotyping of ALOX-5 tandem repeat polymorphism       
The tandem repeat polymorphism was analysed by micro-titre plate (MTP)-sequencing technique, 
using standard 96-well plates. PCR products were prepared from genomic DNA, using MyTaq
TM
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DNA polymerase (Bioline Inc., US) along with the following primers: 5’-
TCAGGAGAGAACGAGTGAAC-3’ (forward) and 5’-GTCCAGGTGTCCGCATC-3’ (reverse). 
Forty reaction cycles were performed at 55°C. From the PCR products, sequencing was performed 
using an ABI 3730XL DNA analyser (Thermo Fischer Scientific Inc., US) and chromatograms 
were interpreted by a laboratory technician, identifying the number of tandem repeats for each 
allele. In case of unclear calls, the chromatograms were rechecked by another technician, and 
results were discussed and agreed upon.  
 
Genotyping of rs12762303 
SNP genotyping was performed by LGC Genomics using the commercially available KASP
TM
 
genotyping assay [22]. The fluorescent signal from the PCR products was analysed using a BMG 
PHERAstar plate reader (BMG Labtech Ltd., Aylesbury, UK). Analysis was performed according 
to the protocol provided by LGC Genomics [23]. SNP alleles correspond to the positive/forward 
DNA strand according to dbSNP, human assembly GRCh38.p2 [24].    
 
Adipose tissue biopsies 
At baseline, adipose tissue biopsies were taken from the buttocks of all participants using a luer 
lock system (Terumo, Terumo Corp, Tokyo, JP) consisting of a needle, a venoject multisample luer 
adaptor, and an evacuated blood tube, according to the method described by Beynen and Katan 
[25]. Samples were flushed with nitrogen and stored at -150°C until analysis. When analysed, 
biopsies were thawed and preheated at 50°C for 10 min. Subsequently, the fat was dissolved in 
heptane at 50°C, and fatty acids were transesterified by 2 mol/L KOH (potassium hydroxide) in 
methanol at 50°C for 2 minutes. The fatty acid composition was determined by gas chromatography 
using a Varian 3900 GC with a CP-8400 autosampler (Varian, Middleburg, NL) equipped with a 
flame ionisation detector. Split injection mode, a CP-sil 88, 50 m x 0.25 mm ID capillary column, 
temperature programming from 90°C to 210°C and constant flow were used. Helium was used as 
carrier gas. Commercially available standards (Nu-chek-Prep, Inc., Minnesota, US) were used to 
identify the individual fatty acids.  
 The content of fatty acids was expressed as weight percent of total fatty acids, and the 
inter assay coefficients of variation were 3.2% and 6.4% for AA and EPA, respectively. 
 
Identification of cases  
From the Danish National Patient Registry and/or the Danish Causes of Death Registry we 
identified all participants in the cohort who were registered with a first time diagnosis of MI, 
according to the International Classification of Disease (ICD) 8 (410.00-410.99) or ICD-10 (I21.0-
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I21.9) coding, during the study period. Furthermore, all cases of cardiac arrest (ICD-8: 427.27 or 
ICD-10: I46.0-I46.9) were included if the arrest was considered to be of cardiac origin after 
validation in each individual case. An earlier study from our department validated the MI diagnosis 
from baseline through 2003 by complete review of all medical records and found a positive 
predictive value above 92% when the diagnoses were obtained from a hospital ward [26]. All 
validated cases of MI from the validation study were readily accepted as cases for the present study. 
From January 2004 through July 2013, all participants with an incident MI diagnosed from a ward 
were accepted as cases without further validation. All other diagnoses of incident MI and cardiac 
arrest were validated by reviewing a complete list of diagnoses and interventional procedures 
recorded in the Danish National Patient Registry for each potential case. 
 
Statistics 
Regarding the ALOX-5 tandem repeat polymorphism we considered five repeats or more (5-6 
repeats) as the wild type allele and alleles with less than five repeats (2-4 repeats) as variant alleles. 
We planned a priory to analyse each copy-number variant separately and collectively according to 
the above definition of variant and wild type alleles.   
 Polymorphisms were categorised according to genotype and analysed with one degree 
of freedom, assuming a recessive model of inheritance. Allele frequencies were tested for Hardy–
Weinberg equilibrium (HWE) in the sub-cohort using a chi-square test (X
2
-test). 
Measures of association were assessed using Cox proportional hazards multivariate 
regression models with age as the time axis and delayed entry. In accordance with the case-cohort 
design, we used a weighting scheme and robust variance estimates as described by Kalbfleisch and 
Lawless [27]. Analyses were conducted for the whole cohort and also separately for men and 
women. Participants were treated as at risk from baseline until either MI, death, emigration or end 
of follow-up occurred.  
 To investigate potential interaction between genotype and adipose tissue content of 
EPA and AA, we cross-tabulated genotype by quintiles of EPA or AA content. Interaction was 
assessed quantitatively by calculation of the "relative excess risk due to interaction" (RERI) that 
describes additive interaction under the sufficient cause model [28,29]. We calculated robust 
variance estimates using bootstrap with 1000 replications for each model.    
To address potential confounding, we adjusted for traditional risk factors for MI 
(model A2) including smoking habits (never, former or current (<15 g/day, 15-25 g/day, >25 g/day) 
smoker), body mass index (kg/m
2
), waist circumference (cm), physical activity (hours/week), 
alcohol intake (g/day), educational level (basic school, higher education: 1-3 years or >3 years) and, 
for women, menopausal status (pre- or post-menopausal). Additionally, we adjusted for medical 
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history (model B) or dietary variables (model C) in separate models. Regarding medical history, we 
included history of diabetes mellitus (yes/no), hypertension (yes/no) and hypercholesterolaemia  
(yes/no) complemented with use of anti-diabetic and/or lipid-lowering drugs. Additional dietary 
variables included dietary fiber (g/day), adipose tissue content of total saturated, monounsaturated, 
and trans fatty acids (percentages of total fatty acids). All continuous variables were included in the 
models as restricted cubic splines with five knots. Potential confounders were selected a priori 
based on current knowledge of the 5-LOX pathway and risk factors for MI.  
The proportional hazards assumption was checked by visual inspection of log-log 
plots and by evaluation of scaled Schoenfeld residuals versus time. P-values (two-tailed) < 0.05 
were considered statistically significant. STATA, version 14.1 (StataCorp, College Station, TX, 
US) was used as statistical software. 
 
5. Results 
Population characteristics 
In total, 57,053 (35%) subjects accepted the invitation and were enrolled into the study. Initially 
1,506 were excluded because of missing baseline questionnaires (n=42), if participants were 
identified with a cancer diagnosis in the Danish National Patient Registry before baseline (n=564) 
or if registered with MI or cardiac arrest before inclusion (n=900). We identified 3,089 cases of 
incident MI during a median follow-up time of 17.0 years. Subjects for whom information 
regarding one or more covariates used in the adjusted analyses were missing (n=346), missing 
DNA-samples (n=255) and subjects with missing adipose tissue data (n=376) were excluded. In 
total, 2,680 cases were included in the analyses, but not all samples were successfully genotyped, 
and therefore, 103 and 86 samples were missing for rs12762303 and rs59439148, respectively.    
 Table 1 describes the cases and the sub-cohort with respect to important baseline 
characteristics. Cases had a higher median age, BMI, waist circumference and a higher proportion 
of smokers, while weekly physical activity and educational level were lower compared to the sub-
cohort. More cases suffered from hypertension, hypercholesterolemia and diabetes mellitus (Table 
1). 
 
Association of ALOX-5 tandem repeat polymorphism with MI 
We genotyped the tandem repeat rs59439148 and calculated genotype frequencies, according to the 
number of hexamer-repeats (‘-CCCGCC-’) for the two alleles (Table 2). The 5-repeats allele was, 
by far, the most common allele (84.4%) and considered as the wild type. Next, the 4-repeats allele 
was the most frequent variant observed (15.2%), whereas alleles with less than 4-repeats were rare 
(<1%). As a consequence of the observed allele frequencies, we analysed the tandem repeat 
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defining the variant allele as alleles with less than 5 repeats (2-4 repeats) and the wild type as alleles 
with 5 repeats or more (5-6 repeats). Table 3 summarises the allele frequencies of the 
polymorphism according to our definition of variant/wild type.   
 Table 4 shows the cross-tabulation of genotype by quintiles (Q) of EPA or AA content 
in adipose tissue. The table displays hazard ratios for the association with incident MI. Looking at 
AA, we found a positive association with MI when comparing Q1 with Q5 for both the reference 
genotype and homozygotes of the variant. Furthermore, the variant genotype was associated with a 
higher risk of MI, comparing homozygotes of the variant with carriers of the wild type. This 
association seemed to be augmented with higher content of AA, in particular for the highest quintile 
(Q5) of AA content where we found a threefold higher risk of MI among homozygotes for the 
variant allele compared with the reference (HR=3.02 95% CI: 1.41;6.44 (model B)). Concerning 
EPA, we observed a trend towards a negative association with MI for increasing content of EPA. 
Accordingly, we selected the highest quintile (Q5) as reference in table 4 to better interpret the 
interaction and found low EPA contents to be associated with a higher risk of MI (HR=1.29, 
95%CI: 1.05;1,58) comparing Q1 with the reference (model B). For the reference group with high 
EPA content, carrier status for the polymorphism did not affect the risk of MI, but for lower 
quintiles of EPA carrier status was positively associated with MI for homozygous carriers of the 
variant compared with carriers of the wild type, most pronounced for Q1 compared to the reference 
with a HR of 2.15 (95% CI: 0.91;5.09) in model B. Associations differed slightly between models.  
 We also performed sex-stratified analyses and found some discrepancies between men 
and women (Supplementary, Table 4a+b). For women, we observed substantial variations between 
models with no evident trend across quintiles and large CIs.              
 
Additive measures of interaction between EPA or AA and ALOX-5 promoter polymorphism  
To evaluate a possible interaction between EPA or AA and genotype quantitatively, we calculated 
the RERI (Table 5). These values reflected the measures of association from Table 4, but estimation 
of robust variance measures by bootstrap revealed no significant interactions between the content of 
EPA or AA and genotype.    
    
Linkage between ALOX-5 tandem repeat polymorphism and rs12762303 
We analysed the association between the SNP, rs12762303, and incident MI, finding very similar 
measures of association to those of the tandem repeat polymorphism (Supplementary, Table 6). 
Using the Haploview software [31], we found this SNP to be in almost perfect LD with the tandem 
repeat polymorphism (D’=0.99).  
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6. Discussion 
Based on the Danish, Diet, Cancer and Health Cohort, we conducted a case-cohort study to 
investigate the interaction between adipose tissue content of EPA and AA and the ALOX-5 tandem 
repeat polymorphism on incident MI. Cross-tabulation of genotype by quintiles of EPA or AA 
content indicated a higher risk of MI for carriers of two variant alleles. While the association 
between genotype and MI seemed to be augmented by higher content of AA compared with the 
reference group with a low content of AA, the opposite was observed for EPA where the 
association seemed to be attenuated by increasing content of EPA. However, interaction on an 
additive scale assessed by calculation of RERIs was not nominally significant.     
 
Strengths and limitations 
The Diet, Cancer and Health study is a large prospective cohort study, and while earlier studies on 
the 5-LOX pathway used a retrospective study design, this study holds the advantages of the 
prospective design. This might be of importance, in particular when assessing combined effects of 
genetics and diet because dietary factors are more sensitive to confounding than genotype 
information alone. Exposure to EPA and AA was assessed by adipose tissue content of the 
respective fatty acids which reflects the average long-term (1-3 years) exposure to these fatty acids, 
and as a biomarker it may represent the true endogenous exposure more precisely than a dietary 
assessment of fatty acids intake [13,14]. Concerning outcome assessment, there was a very limited 
loss to follow-up, and all diagnoses of MI or cardiac arrest were either validated from review of 
medical records or from a complete list of diagnoses and medical procedure codes, ensuring a high 
validity of cases. The cohort was well characterised at baseline regarding demographic data, 
anthropometrics, dietary and other lifestyle factors, which allowed for adjustment of potential 
confounding [21]. 
 We applied adjustments for potential confounding in different layers. First, a basic 
layer adjusting for well-established demographic and lifestyle risk factors for MI (model A2). Next, 
we applied an additional layer including medical history (model B) or dietary factors (model C). 
Only minor variations between models were observed, and generally, measures of association and 
the conclusions were similar for the various models. We consider model B as our primary model, 
but all models are included in the tables.  
 The study also had limitations. Even though the study included a high number of cases 
with both genotype and adipose tissue information, the number of homozygote carriers of the 
variant genotype was limited, in particular when cross-tabulated by quintiles of fatty acids content. 
This made assessment of interaction difficult, and stratifying further by sex did not yield a 
meaningful comparison in women because of the low number of cases. The median follow-up was 
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17.0 years, and lifestyle or dietary measures were not re-evaluated during the study period. A long 
follow-up allowed us to accumulate more outcome events, but subjects might change their lifestyle 
and habits over time. Also, public awareness of disease prevention and changes in standard medical 
care might influence on the participants’ risk profile and limit our ability to address confounding.   
 
General discussion 
Since the Hallmark study by Dwyer et al. from 2004 [15] reported the ALOX-5 tandem repeat 
polymorphism (rs59439148) to be associated with higher intima-media thickness, a number of 
studies have investigated this polymorphism on other relevant endpoints, e.g. patients with MI and 
coronary artery disease verified by angiography. Notably, two independent case-control studies in 
MI patients with Northern European origin (Caucasians), did not find an association between MI 
and variants of the polymorphism [17,18]. In a mixed population of Caucasians and African 
Americans, Hartiala et. al demonstrated a positive association, but only in African Americans [19]. 
In general, the previous studies had a limited size and none of the studies examined the influence of 
diet. A recent study by our group (data not published) investigated the overall association between 
rs59439148 genotypes and MI and found a positive association when comparing homozygotes for 
the wildtype with homozygotes for the variant. However, results were only statistically significant 
in men (HR=1.63, 95% CI: 1.06;2.52), while the pooled analyses were borderline significant 
(HR=1.35, 95% CI: 0.96;1.90).  
 In the present study, our results indicated a positive association between carriers of 
two variant alleles and MI when compared with the reference genotype, but the association was 
only statistically significant when comparing homozygotes for the variant genotype in the high 
stratum of AA content with the reference group. Furthermore, the associations were highly 
dependent on the content of EPA and AA in adipose tissue, where a high content of EPA seemed to 
blunt the effect of the polymorphism, while a high content of AA seemed to exacerbate the effect. 
However, measures of interaction on an additive scale were not statistically significant. The initial 
study by Dwyer et. al [15] was also the first study to suggest interaction between dietary intake of 
5-LOX substrates and the tandem repeat polymorphism, well in line with our findings. Later, the 
same group performed a large study on Costa Rican nationals, including 1,885 cases of MI [16], 
with no overall effect from the variant genotype, but the group with a high intake of AA had a 
significantly higher risk of MI when the variant genotype was present indicating interaction 
between AA intake and genotype. No interaction could be detected for marine n-3 PUFA. Both 
studies used dietary questionnaires to assess the intake of fatty acids, while our study used adipose 
tissue content as a biomarker reflecting long-term dietary intake or, more precisely, the endogenous 
exposure to the respective fatty acids. 
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 In addition to the tandem repeat polymorphism, we genotyped the SNP rs12762303 
that is located only 409 base pairs upstream from the tandem repeat and was previously described to 
be in close LD with rs59439148 [30], confirming that these two polymorphisms were in almost 
perfect LD. In future studies, it may be relevant to genotype the more cost-efficient SNP, 
rs12762303, instead of the tandem repeat polymorphism. 
 Studies have examined other polymorphisms in ALOX-5 [19,30], but none of these, 
other than rs59439148 and SNPs linked to this polymorphism, has been associated with 
atherosclerosis traits. Furthermore, a number of studies have supported a role for other candidate 
genes in the 5-LOX pathway [32–34], but replication studies have been inconclusive, and despite 
great efforts, studies have not been able to agree upon functional polymorphisms in any of the other 
candidate genes, except ALOX-5.   
 One of the key mechanisms linking the 5-LOX pathway to the development of 
atherosclerosis may be attributed to the formation of LTs and their pro-inflammatory properties. 
LTs increase vascular permeability and act as potent chemo attractants among other pro-
inflammatory functions [4,35]. Furthermore, a high expression of multiple 5-LOX enzymes has 
been found in human atherosclerotic plaques and linked to the stage of plaque development [36,37]. 
Genetic association studies have also provided some evidence of a link between the 5-LOX 
pathway and atherosclerotic disease, and in this regard, our study adds to the body of evidence in 
support of this hypothesis, confirming the tandem repeat polymorphism in ALOX-5 (rs59439148) as 
a functional polymorphism. Finally, our results indicated an interaction between fatty acid 
substrates for the 5-LOX enzymes and rs59439148 which is well in line with the hypothesis that the 
differential roles of marine n-3 PUFA and AA in atherosclerotic disease states may, at least partly, 
be explained by the formation of less inflammatory LTs derived from EPA compared to AA. The 
present study also adds mechanistic evidence for the role of marine n-3 PUFA and AA in MI 
through the 5-LOX system.     
 
Conclusion 
The present study indicated that homozygote carriers of the variant genotype had a higher risk of 
incident MI compared with carriers of the wild type, and this association was modulated by adipose 
tissue content of EPA and AA. Thus, results suggested that the association was augmented by  
intake of AA, while EPA attenuated the association. However, the interaction was not statistically 
significant when evaluated by calculation of RERIs.  
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Variable
Age (years) 56.3 (51.2;63.2) 57.7 (51.7;63.9) 56.3 (51.1;62.9) 59.2 (52.4;64.1)
Physical activity (hours/week) 2.5 (0.0;8.5) 2.0 (0.0;8.0) 2.5 (0.0;8.0) 2.0 (0.0;7.0)
BMI (kg/m2) 26.4 (23.0;31.2) 27.0 (23.4;32.3) 24.6 (20.9;31.1) 26.1 (21.1;33.5)
Waist circumference (cm) 95.5 (86.0;109.0) 97.0 (87.0;112.0) 80.0 (69.0;97.0) 84.0 (70.0;102.0)
Alcohol intake (g/day) 19.4 (3.3;61.9) 18.2 (2.5;62.3) 9.4 (1.2;34.8) 6.5 (0.5;32.3)
Smoking (% (n))
Never smoker 25.8 (375) 18.4 (353) 43.7 (546) 28.3 (214)
Former smoker 35.4 (515) 29.5 (567) 22.8 (285) 19.3 (146)
<15 g/day 11.4 (165) 12.9 (248) 16.1 (201) 22.1 (167)
15-25 g/day 16.6 (242) 23.5 (453) 14.7 (184) 25.0 (189)
>25 g/day 10.8 (157) 15.8 (303) 2.7 (34) 5.3 (40)
Educational level (% (n))
Basic school 33.9 (493) 43.4 (835) 32.0 (400) 44.2 (334)
Higher education, 1-3 years 42.4 (617) 37.1 (713) 49.7 (621) 46.4 (351)
Higher education, >3 years 23.7 (344) 19.5 (376) 18.3 (229) 9.4 (71)
Menopausal status (% (n))
Post-menopausal - - - - 59.4 (742) 70.1 (530)
Pre-menopausal - - - - 31.4 (392) 17.1 (129)
Medical history (% (n))
Hypertension 14.8 (215) 22.6 (434) 16.7 (209) 31.8 (240)
Hypercholesterolaemia 8.5 (123) 12.3 (236) 6.2 (77) 13.4 (101)
Diabetes mellitus 3.0 (43) 5.2 (99) 1.4 (17) 4.5 (34)
Adipose tissue (%, of total fatty acids)
EPA 0.1 (0.1;0.2) 0.1 (0.1;0.2) 0.1 (0.1;0.2) 0.1 (0.1;0.2)
AA 0.3 (0.2;0.5) 0.4 (0.2;0.5) 0.4 (0.3;0.5) 0.4 (0.3;0.6)
Continuous variables are reported as medians (10th;90th percentile) and categorical variables as percent (n).
Abbreviations: BMI, Body mass index; EPA, Eicosapentaenoic acid; AA, Arachidonic acid.
Baseline characteristics of the sub-cohort and cases 
TABLE 1
Sub-cohort (n=1,250) Cases (n=756)
Men Women
Cases (n=1,924)Sub-cohort (n=1,454)
Genotype
- - - -
- - - -
2 (0.08) 2 (0.08)
16 (0.60) 10 (0.38)
- - - -
- - - -
3 (0.11) 1 (0.04)
1 (0.04) 3 (0.11)
- - - -
71 (2.66) 78 (2.97)
671 (25.17) 630 (23.98)
- - - -
1,902 (71.34) 1,902 (72.40)
- - - -
- - 1 (0.04)
2,666 2,627
66
Total
44
45
46
55
56
Reported as number of subjects with 
frequencies in parentheses (%). No 
observations are indicated with a dash. 
Sub cohort
TABLE 2 
22
23
24
25
26
33
34
35
36
Cases
Distribution of genotypes for rs59439148, 
according to number of tandem repeats (5'-
GGGCGG-3')
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